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Role of cap 1 and cap 2 2ʼ-O-ribose methylation in Drosophila development and 
nervous system function (Page 1) - The presence of cap 1 and cap 2 2ʼ-O-ribose 
methylation on the second and third nucleotide of mRNA has been known for more 
than 30 years however studies into the role of these methylations are very limited. 
Research has shown that Cap 1 methylation may be related to translational efficiency 
however no studies have shown a role for Cap 2 methylation. This study aims to 
extend the understanding of the function of these methylations in the neural 
development of Drosophila. 
LIM Domain Only Proteins, LMO1 and LMO4 in Hematopoiesis (Page 72) - The 
LIM Domain Only (LMO) proteins have been shown to play a major role in cellular 
differentiation and development at the embryonic stage and in many human cancers. 
The aim of this study was to develop tools to perform overexpression and knockdown 
experiments with LMO1 and LMO4 proteins in murine early stage hematopoietic 
progenitors and ES cells in an attempt to identify their function. Preliminary results 
show a possible apoptotic effect of LMO4 knockdown in myeloid progenitor cells. 
This study provides the basis for future research into these proteins.
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The presence of cap 1 and cap 2 2ʼ-O-ribose methylation on the second and third 
nucleotide of mRNA has been known for more than 30 years however studies into 
the role of these methylations are very limited. Past studies have shown a potential 
link to increase in translational efficiency by the presence of cap 1 methylation 
however there is little information for the role of cap 2 methylation. This study 
attempts to contribute to the understanding of these functions through the study of 
cap methylation in D.melanogaster. A number of trials were carried out looking for a 
link to neural plasticity through the use of ion channel blocking compounds and 
interaction with the TOR pathway through dietary restriction.  When the ion channel 
blockers, Ethosuximide and Propranolol , were applied the survival rate of Cap2null 
mutants was decreased more than in Cap1null mutants, however Cap2null mutants 
were least effected by nutrient depravation. The results show some potential areas 
for further research to further elucidate the roles of cap 1 and 2 mRNA methylation.
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Figure 1.1 - 5ʼ end of mRNA molecule showing cap 0, 1 and 2 methylation on the first 
second and third nucleotides respectively (Kruse, et al. 2011 & Werner, et al. 2011)
Figure 1.2 - Phylogenetic tree for hMTr1 gene, numbers show the percentage of 
bootstrap support (Zamudio, et al. 2007).
Figure 1.3 - Interactions between mRNA cap methylation, the translation initiation 
complex and the TOR pathway (Penney, et al. 2012, Kruse, et al. 2011, Li, et al. 
2010, Costa-Mattiolo, et al. 2009).
Figure 2.1 - Experimental timeline for application of compoundʼs and counting of 
hatched flies.
Figure 3.1 - Total percentage of adult flies emerging from 50 embryos in an 18 day 
period after egg laying. Comparing nutrient restricted food types to cap methylation 
mutant genotypes. There were no survivors for the Cap2null flies on Y2% food. Error 
bars show standard deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 
2null - aftnull and  Cap 1null Cap 2null (CG6379null; aftnull).
Figure 3.2 Developmental delay graphs showing emergence of adult flies from 50 
embryos over an 18 day period from egg laying on nutrient restricted food types. a) 
Normal food, b) yeast reduced to 20 %, c) yeast reduced to 2%, d) no dextrose, e) all 
nutritional constituents reduced to 40%. C - Yellow White Mutant, Cap1null - 
CG6379null, Cap 2null - aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure 3.3 - Negative geotaxis performance index for female and male cap mutant D. 
melanogaster on nutrient reduced food types. Error bars show standard deviation. 
The genotypes not assayed due to lack of flies were Cap1null Y2%, Cap2null Y2% and 
Cap12null F40%, S0,Y2% and Y20%.  F - Normal food, Y20% - yeast reduced to 20 
%, Y2% - yeast reduced to 2%, S0 - no dextrose, F40%  - all nutritional constituents 
reduced to 40%. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - aftnull 
and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure 3.4 - Example of body length measurement technique of D. melanogaster
Figure 3.5 - Sizes of D.melanogaster cap mutant flies on reduced nutrient food types. 
Error bars show standard deviation. Assays were not carried out on Y2% Cap1null and 
Cap2null  and Y20% Cap12null due to a lack of surviving flies. F - Normal food, Y20% - 
yeast reduced to 20 %, Y2% - yeast reduced to 2%, S0 - no dextrose, F40%  - all 
nutritional constituents reduced to 40%. C - Yellow White Mutant, Cap1null - 
CG6379null, Cap 2null - aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure 3.6 - Average size across all mutant genotypes on each nutrient restricted 
food type. Error bars show standard deviation. F - Normal food, Y20% - yeast 
reduced to 20 %, Y2% - yeast reduced to 2%, S0 - no dextrose, F40%  - all 
nutritional constituents reduced to 40%.
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Figure 3.7 - Trial of D.melanogaster mRNA cap methylation mutants with various 
compounds applied to larvae, 2 days post egg laying. C - Yellow White Mutant, 
Cap1null - CG6379null, Cap 2null - aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure. 3.8 - Percentage emergence of mRNA cap mutant D.melanogaster treated 
with varying concentrations of the ion channel blocking compounds a) Ethosuximide. 
b) Propranolol c) Carbamazepine. C - Yellow White Mutant, Cap1null - CG6379null, 
Cap 2null - aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure 3.9 - Number of mRNA cap mutant D.melanogaster treated with 25mM 
Ethosuximide hatching over  period up to 18 days from initial egg laying. Error bars 
show standard deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - 
aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure 3.10 - Average percentage emergence from 50 mRNA cap mutant 
D.melanogaster embryos treated with varying concentrations of the ion channel 
blocking compounds a) Ethosuximide b) Propranolol and c) Carbamazepine. C - 
Yellow White Mutant, Cap1null - CG6379null, Cap 2null - aftnull and  Cap 1null Cap 2null 
- CG6379null & aftnull.
Figure 3.11 - Number of mRNA cap mutant D.melanogaster hatching over period up 
to 18 days from initial egg laying after treatment with the ion channel blocking 
compound ethosuximide. a) 4mM, b) 10mM, c) 25mM Error bars show standard 
deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - aftnull and  Cap 
1null Cap 2null - CG6379null & aftnull.
Figure 3.12 - Number of mRNA cap mutant D.melanogaster treated with 4mM 
propranolol hatching over period up to 18 days from initial egg laying. Error bars 
show standard deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - 
aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
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INTRODUCTION
In 2000 the sequencing of the entire human genome was completed and was 
heralded as the answer to many biological and genetic questions. This information 
however serves little purpose without understanding how the expression of these 
genes is controlled (Orphanides & Reinberg, 2002). Control of gene expression is an 
essential process for both prokaryotes and eukaryotes and is particularly important in 
complex multi-cellular organisms. Almost every cell in an organism  has the potential 
to express every gene within its genome however this has to be controlled to allow 
the creation of the many specialised cells found throughout a complex organism. 
Gene expression is also controlled by environmental factors, particularly in single 
cellular organisms but also in more complex organisms. Understanding the different 
pathways for gene expression control is essential for making use of the information 
obtained from genome sequencing projects and has the potential for development of 
new medicines and treatments. 
Central to this whole regulatory process is the way in which proteins are produced 
from DNA. There are two basic stages in this process, transcription, the conversion 
of genes in the DNA sequence to mRNA and translation, the conversion of the 
mRNA sequence into amino acids which then form a polypeptide chain which can 
fold to produce the tertiary structure of a protein (Campbell, et al. 2008). Transcription 
is a three stage process, in the first stage, initiation, RNA polymerase binds to a 
specific promoter site on the DNA sequence. In eukaryotes this binding is mediated 
by  a group of proteins known as transcription factors. Transcription factors have to 
be present and bind to the promoter site to allow RNA polymerase to bind, this is 
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known as the transcription initiation complex. Once bound, RNA polymerase begins 
to unwind and separate the double DNA strand to allow access to the nucleotide 
bases. During the next stage, elongation, the RNA polymerase moves along the 
DNA strand, from the 3ʼ to 5ʼ end, creating a complementary RNA strand and 
allowing the DNA to rewind behind it. In the final stage, termination, the RNA 
polymerase disassociates from the DNA strand releasing the completed RNA strand 
(Campbell, et al. 2008). During the transcription process the newly produced RNA 
strand undergoes pre-mRNA processing to modify the RNA ready for translation 
outside the nucleus at ribosomes in the cytoplasm.
Translation then takes place at ribosomes within the cell cytoplasm. During 
translation the mRNA passes through a ribosome which enables tRNA interpreters to 
bind to complimentary sequences in the mRNA. Each of the tRNA molecules has an 
anticodon on one end and the complimentary amino acid on the other, as these bind 
to the mRNA they leave behind the amino acids producing a polypeptide chain. Once 
complete the polypeptide chain will then be able to fold into a protein (Campbell, et 
al. 2008).
Gene Expression Control
There are a number of points throughout this DNA to Protein pathway at which gene 
expression can be regulated. These include transcriptional initiation, post 
transcriptional modification, translational initiation and post translational modification 
(King, 2013). The majority of expression control in eukaryotes is carried out at the 
transcriptional initiation stage this either occurs through limiting access to the  DNA 
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by either chromatin modifications or DNA methylation or during recruitment of 
transcription factors (Hoopes, 2013). Transcription factors are required in eukaryotes 
to allow for the binding of RNA polymerase II to the DNA strand and by modifying the 
availability of transcription factors this can control initiation of transcription (Campbell, 
et al. 2008). 
If transcription is able to take place the next gene expression control points are in the 
RNA processing stages prior to translation. There are a number of processes which 
occur to prepare an mRNA strand for translation. These include capping, splicing and 
packaging, which are important processes to protect the mRNA from degradation, for 
its successful transportation to the ribosomes and to allow initiation of translation 
(Soller, 2006). By limiting any of these modifications the gene expression process 
can be slowed or completely halted. If the mRNA has been fully processed and it 
successfully reaches the ribosomes controls can also be applied at the translational 
initiation stage. The mRNA has to bind to the translation initiation complex, this 
binding can be limited by both the modifications applied to the mRNA during 
processing and the presence of 4E-BPʼs (4E Binding Proteins) which act as inhibitors 
on the translation initiation complex (Penney, et al. 2012). The final stage of gene 
expression regulation acts following translation on the amino acid sequence and the 
folding and transportation of the protein, this can include methylation, acetylation and 
disulphide bond formation amongst many other processes (King, 2013).
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Pre-mRNA Processing
This study focuses on the controls in the post-transcription and translation initiation 
stage of the gene expression process. Before RNA can be transported from the 
nucleus for translation it has to undergo a number of modifications to become a 
mature mRNA strand and be packaged into a ribonucleoprotein complex (mRNP) to 
allow it to pass through the pores in the nuclear membrane. There are four main 
modifications which occur during this processing, 5ʼ end capping, splicing, 
polyadenylation and packaging (Carmody & Wente, 2009). The first modification to 
occur is capping of the 5ʼ end which happens after the first 20-30 nucleotides have 
been added to the RNA Strand (Moore & Proudfoot, 2009 & Carmody & Wente, 
2009). This cap serves a number of purposes, in particular the prevention of 
degradation by nuclease enzymes within the cell (Orphanides & Reinberg, 2002). 
The basic cap is a 7-methyl guanosine cap on the first nucleotide in the transcript, 
this is referred to as cap 0 and found in animals, plants and yeast. In animals there is 
also potential for methylation of the two following nucleotides, known as cap 1 and 
cap 2 methylation (Kruse, et al. 2011).
The second modification which occurs to pre-mRNA is splicing which involves the 
removal of introns, leaving only the exons which code for the required amino acids. 
This is done by an assembly known as the spliceosome, which is composed of small 
nuclear ribonucleoproteins (snRNPs) (Campbell, et al. 2008). The pre-mRNA 
molecule also undergoes polyadenylation, gaining a poly-A-tail of between 50 and 
250 adenine molecules on the 3ʼ end. This partially serves a similar purpose to the 5ʼ 
capping, acting to protect the RNA from degradation (Campbell, et al. 2008). If this 
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processing isnʼt completed successfully the mRNA molecule will be degraded by 
processes such as non-sense mediated decay (Cheng, et al. 2006). 
In the final stage of mRNA processing it is packaged into messenger 
ribonucleoprotein (mRNP) complexes which are composed of the mRNA and a 
number of proteins to assist with transport out of the nucleus and the initiation of 
translation (Hieronymus & Silver, 2004). The mRNP complexes are transported out of 
the nucleus through nuclear pore complexes (NPCs) (Carmody & Wente, 2009). 
5ʼ Cap Methylation
The particular area of interest for this study is the 2ʼ-O-ribose methylation which can 
occur as part of 5ʼ capping on the second and third neucleotides of mRNA, known as 
cap 1 and cap 2 (Kruse, et al. 2011). As previously explained all mRNA gains a 7-
methyl guanosine cap on its first nucleotide at the 5ʼ end (cap 0) (fig 1.1). This is 
essential in mammalian cells as without this cap the RNA strand would be degraded 
(Werner, et al. 2011). This cap is formed by the process of three enzymes, a 
triphosphatase which causes hydrolysis of 5ʼ γ-phosphate, a guanyltransferase which 
adds a guanine monophosphate nucleoside and a methyl transferase which 
methylates the N7 position of the guanine molecule (Moore & Proudfoot, 2009, 
Soller, 2006 & Ghosh & Lima, 2010). Often in higher eukaryotes the triphosphatase 
and guanyltransferase are combined into one enzyme with 2 active sites (Belanger, 
et al. 2010). It is believed that cap 0 formation is a co-transcriptional process with the 
methyltransferase enzyme binding to the c-terminal domain of RNA polymerase II 
during transcription meaning that this is the first modification which occurs to the 
RNA strand (Belanger, et al. 2010). It has been suggested that as well as preventing 
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degradation by exonucleases, this cap effects the efficiency of translation, the 
initiation of translation and splicing, 3ʼ end processing and neucleocytoplasmic 
transport (Soller, 2006, Belanger, et al. 2010, Werner, et al. 2011, Kruse, et al. 2011). 
It is thought that the cap 0 methylation interacts with the nuclear binding complex 
which is why it influences the formation of the 3ʼ end and also splicing (Kruse, et al. 
2011). The influence of cap 0 methylation on translation efficiency mainly stems from 
its interaction with eIF4E (Eukaryotic translation initiation factor 4E) which is part of 
the eIF4F cap binding complex (Kruse, et al. 2011 & Costa-Mattiolo, et al. 2009). 
Figure 1.1: 5ʼ end of mRNA molecule showing cap 0, 1 and 2 methylation on the first 
second and third nucleotides respectively (Kruse, et al. 2011 & Werner, et al. 2011).
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Some studies suggest that cap 1 and cap 2 methylation are formed sequentially after 
the cap 0 formation, however both cap 1 and cap 2 methylation can occur without the 
presence of other methylation (Werner, et al. 2011). It has however been shown that 
the presence of cap1 increases the efficiency of cap 2 methylation (Werner, et al. 
2011). It is thought that in Humans cap 1 methylation is found on all mRNA molecules 
and cap 2 is found on around half, however there is no study of the frequency of its 
occurrence in other organisms (Belanger, et al. 2010 & Werner, et al. 2011). 
Cap 1 and Cap 2 are 2ʼ-O-methylations on the first and second nucleotides 
respectively and are produced by two different methyltransferase enzymes. In 
humans these are know as hMTr1 and hMTr2 and were first identified in HeLa cells 
over 30 years ago by Langberg & Moss (1981) however there is a lack of research 
into the exact functioning of these proteins. hMTr1 is found only within the nucleus 
meaning that cap 1 methylation must occur before the mRNA strand is transported 
out of the nucleus and may occur co-transcriptionally  in the same way as cap 0 
formation (Werner, et al. 2011 & Belanger, et al. 2010). Some studies have shown 
that the presence of cap 1 promotes binding to ribosomes and therefore increased 
translational efficiency in vitro, there is however no evidence in current studies that 
this causes any developmental or phenotypic effects in vivo (Kruse, et al. 2011 & 
Belanger, et al. 2010).
The hMTr2 protein is found throughout the cell including the nucleus, however it is 
mainly active in the cytoplasm with <5% activity in the nucleus (Werner, et al. 2011). 
It has been shown that hMTr2 can function without cap 1 methylation being present 
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but at much reduced efficiency (Werner, et al. 2011). The purpose of cap 2 
methylation is largely unknown however a study by Werner, et al. (2011) has shown 
that mRNA strands with all 3 caps present have a higher affinity to ribosomes 
indicating increased transcriptional efficiency. There is also currently no study to 
suggest why cap 2 methylation is present on some mRNA strands and not others and 
whether this is just randomly occurring.
Another type of methylation is possible when the second nucleotide is adenosine 
which can become methylated at the N6 position, known as m6Am. This methylation 
occurs alongside regular cap 1 methylation and is produced by a unique 
methyltransferase which is mainly active in the cytoplasm. It has had very limited 
study and the purpose and frequency of it is currently unknown (Kruse, et al. 2011).
5ʼ Cap Methylation in Viruses
Kruse, et al. (2011) suggest that cap 1 methylation must be important as many 
viruses encode their own methylase enzymes to form cap 1 methylation. This is 
particularly seen in viruses which are active in the cytoplasm such as west nile virus 
and vesicular stomatitis virus supporting the theory that cap 1 formation is usually 
carried out in the nucleus (Daffis, et al. 2010). It is thought that these viruses encode 
methyltransferase enzymes to produce cap 1 methylation to reduce the host cells 
immune response (Kruse, et al. 2011). Daffis, et al. (2010) showed that the presence 
of cap 1 in viral mRNA reduced the activation of IFIT genes which are known to 
restrict translation. This possibly evolved as an immunity method to allow cells to 
differentiate between host and viral mRNA. No viruses have been reported which 
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encode for cap 2 or m6Am methylases, however viral mRNA can gain this 
methylation through action of the host cell methylases. 
mRNA cap methylation in Drosophila Melanogaster
The orthologs to the human hMTr1 and hMTr2 genes in D. melanogaster are know 
as CG6379 and aft, they have amino acid similarities of 30% and 40.27% 
respectively (GeneCards, 2013a & GeneCards, 2013b). This suggests that 
D.melanogaster is a good model organism to relate any findings back to humans. 
They are also shown to be close evolutionary relatives for these genes on the 
phylogenetic tree (fig 1.2).
Figure 1.2 Phylogenetic tree for hMTr1 gene, numbers show the percentage of 
bootstrap support (Zamudio, et al. 2007).
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Translation Efficiency and Synaptic Homeostatic Control
To allow the nervous system to have plasticity which is required during development, 
growth, memory formation and learning, synapses need to have a system of 
homeostatic control (Turrigiano, 2008). A number of different routes for this control 
have been proposed, the most significant of which are changes in the expression of 
post-synaptic receptors and retrograde control of neurotransmitter release (Penney, 
et al. 2012). It is believed that these are mainly regulated by translation (Costa-
Mattiolo, et al. 2009).    
Most regulation of translation in eukaryotes occurs at the initiation stage where a 
ribosome is recruited to an mRNA strand. Initiation is a 3 stage process, firstly a 43S 
ribosomal pre-initiation complex is formed, mRNA is then bound to this complex 
before the 80S ribosomal complex formation (Costa-Mattiolo, et al. 2009). The most 
common control point in this process is at the cap binding protein eIF4E. This protein 
works in a complex known as eIF4F which also comprises an RNA helicase enzyme 
to unwind the secondary structure of the 5ʼ UTR (eIF4A) and a pair of bridging 
proteins to bind the mRNA to the 43S pre-initiation complex (Costa-Mattiolo, et al. 
2009). eIF4E can be inhibited by 4E-BPʼs (4E Binding Proteins) and will also not bind 
to an mRNA molecule without the cap 0 methylation being present (Penney, et al. 
2012). Some studies have also suggested that the presence of cap 1 may increase 
the recognition and binding ability of the mRNA to eIF4E (Kruse, et al. 2011). 
However there are currently no studies to suggest what, if any effect, the presence of 
cap 2 methylation has on the efficiency of this binding.
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The TOR (Target of Rampmyecin) pathway is also thought to play an important role 
in regulation at the translation initiation stage and therefore potentially synaptic 
homeostasis (Penney, et al. 2012). Studies have shown that organisms which 
receive reduced nutrient intake tend to experience an increase in life span as a result 
of reduced activity in the TOR pathway (Layalle, et al. 2008). This is thought to be 
partially due to the absence of TOR pathway activity reducing the rate of translation 
(Penney, et al. 2012). Under normal circumstances TOR interacts with the eIF4F cap 
binding complex in two ways. Firstly TOR phosphorylates 4E-BPʼs which prevents 
them from being able to bind to eIF4E. This reduces the level of inhibition taking 
place and leaves more available protein to bind to mRNA 5ʼ Caps to initiate 
translation (Teleman, et al. 2005). TOR also phosphorylates S6K, which amongst 
other actions results in the phosphorylation of eIF4B, which in turn promotes the 
helicase function of eIF4A increasing its ability to unwind the 5ʼ UTR section of the 
mRNA (Penney, et al. 2012). This means that in a condition of reduced nutrients 4E-
BPʼs and the absence of S6K phosphorylation would result in much reduced 
translational efficiency (fig 1.3). 
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Figure 1.3 Interactions between mRNA cap methylation, the translation initiation 
complex and the TOR pathway (Penney, et al. 2012, Kruse, et al. 2011, Li, et al. 2010 
& Costa-Mattiolo, et al. 2009).
To assess the influence which cap 1 and 2 methylation have on drosophila 
development and nervous system function through the regulation of translation this 
research follows several paths. As it has been shown that reduced nutrient intake 
results in less activity in the TOR pathway and therefore an increase in translational 
efficiency a study of  CG6379null and aftnull mutant flies with reduced nutrient intake 
should demonstrate whether these methylations result in increased translational 
efficiency. Trials were also carried out using ion channel blocking compounds and 
neurotransmitters to establish whether cap mutants would be able to homeostaticly 
balance their synapses to live and grow normally. The most likely root for any effect 
would be if the absence or presence of cap 1 or 2 methylation increased or 





Stocks of flies of each genotype were created in the lab as part of a previous project. 
The four genotypes used were a CG6379null mutant which results in an absence of 
cap 1 methylation, an aftnull  mutant preventing cap 2 methylation and a double 
mutant with neither gene so with an absence of both cap 1 and 2. The flies used as a 
control in all experiments were yellow/white mutants as this was the background 
genotype of the cap mutants. The Cap mutants were produced as part of a previous 
project having deletions starting at the P-element in the promoter and deleting the 
catalytic domain of the genes. After production of these flies their genotype was 
checked by PCR (results not shown).
All stocks were stored at room temperature on either standard or +20% yeast fly food 
medium as detailed below. All experimental work, unless otherwise stated, was 
carried out incubated at 25°C in a humidity controlled incubator with a 12:12 hour 
light:dark cycle. When anesthetisation was required for counting or sorting of flies a 
CO2 jet or pad was used and the time kept to a minimum to prevent any long term 
damage to the flies.
Fly Food Medium
Medium for all trials was produced using a standard method and recipe although 
some trials used an increased nutrient food with 20% additional yeast (table 2.1). 
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Table 2.1 Ingredients for standard drosophila food medium.







Yeast 30 g (+20% = 36g)
The medium was produced by boiling the water, agar and nipagin until all agar was 
dissolved. The dextrose, cornmeal and yeast were then added and the mixture was 
stirred continually and heated until a smooth consistency was achieved. The medium 
was then dispensed into plastic and glass vials with approximately 10ml in each vial. 
Once cooled the vials were then plugged with cotton wool and refrigerated until 
needed. When used for most purposes a small amount of dry yeast was added to the 
top of the medium to provide additional food for the adult flies. 
Nutrition Trial
A study was carried out on the effect of varying the nutritional components supplied 
to the flies of the four different genotypes. Five different food types were setup, two 
with reduced yeast at 20% and 2%, one with no dextrose, one with all nutritional 
components reduced to 40% and finally a control of standard food (Table 2.2). 
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10 10 10 10 10
Dry Yeast 20 4 0.4 20 8
Cornmeal 100 100 100 100 40
Dextrose 85 85 85 0 34
Nipagin (ml) 20 20 20 20 20
Each food type was made using the standard procedure of heating the water and 
agar until boiling and fully dissolved. Then adding the other ingredients before 
reheating and mixing thoroughly. The food was then dispensed into plastic vials with 
10ml in each vial. Once cooled and solidified 50 embryos were added to each vial 
and this was repeated in triplicate for each genotype on each food type. 
To allow for the embryos to be collected cages were set up for each genotype. Each 
cage was fitted with a plate with a red grape juice gel (table 2.3) and a small amount 
of yeast paste in the centre. These plates were then changed twice a day to allow for 
the collection of fresh embryos. Embryos were collected by washing the plates with 
distilled water and then filtering the solution which was produced. The residue was 
then removed from the filter paper and resuspended in water to allow for the embryos 
to be counted and placed into the vials. 
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Table 2.3 - Components of red grape juice gels for cage plates.
Ingredients Quantity for 250ml
Technical agar 5.6g
Tap Water 200ml
Red grape juice 
concentrate
50ml
The vials were then incubated at 25°C and the flies which emerged were counted at 
10, 12, 14, 16 and 18 days. After counting on each occasion the flies were removed 
and stored in vials containing standard food to allow for further phenotypic study.
Phenotypic Studies - Negative Geotaxis
Negative geotaxis is a method for assessing the motor abilities of flies by assessing 
their climbing ability. This was used to study any effect on motor ability resulting from 
adjusted nutrient intake across the studied genotypes. This method has been 
published previously by Kerr, et al. (2009) and also in numerous other papers. Flies 
were briefly anaesthetised using CO2  before being separated by gender with 10 flies 
placed in each of a number of vertical column measuring 25cm in length and 
approximately 1.5cm in diameter (modified from plastic 25ml pipettes). Dependent on 
the number of flies available this was repeated in triplicate for each genotype on each 
food type. The columns were then placed in a 25°C incubator for 30 minutes to allow 
the flies to fully recover from the anaesthetic. After this the flies were given a trial run 
of negative geotaxis by tapping them to the bottom of the columns and allowing them 
to climb for 45 seconds. Once this was complete flies in each column in turn were 
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tapped to the bottom and then allowed to climb for 45 seconds before observing and 
recording the number at the top and bottom of the column. This was repeated 3 times 
for each column allowing a gap of around 1 minute between trials. An effort was also 
made to try and maintain a similar number and intensity of taps between columns 
and trials.
The results of this study were analysed by calculating the performance index. This 
was achieved by taking averages from the repeats to give a single result for, total 
number of flies, number of flies at the top and number of flies at the bottom for each 
genotype on each food type. The performance index was then calculated as follows, 
PI = 0.5 x (ntotal + ntop - nbottom) / ntotal.
Phenotypic Studies - Adult Body Length
Another phenotypic analysis carried out was the measurement of overall body length 
in adult flies. This was carried out on both the nutrient restricted flies and also flies 
which had been treated with propranolol as these appeared to visually show a slight 
size difference between genotypes. To achieve these measurements flies were 
anaesthetised with CO2 before being separated by gender and then fixed to 
microscope slides by means of clear PVA glue. An effort was made to try and align 
the flies on their side and in a straightened body position to assist with accurate 
measurement. These slides were then photographed using a microscope fitted with a 
camera and measurements were carried out using the software ʻImageJʼ which was 
calibrated with a millimetre square grid.
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Compound Assay 
Compound assays were setup to determine the effect of a range of ion channel 
blocking compounds on the cap mutant flies. The first compound assays used a fairly 
broad range of compounds known to block various ion channels and included a 
common neurotransmitter (table 2.4)
Table 2.4 Preliminary compound trials showing solvents and required dilution from 
dry form.
Compound Solvent Molecular Weight Quantity of 
compound to make 





Ethosuximide Water 141.17 705.85
GABA Water 103.12 515.6
Carbamazepine Ethanol 236.27 1181.35
Na Valporate Water 166.19 830.95
Propranolol Water 295.8 1479
To trial the compounds 10 vials were setup for each genotype, each of which 
contained 3 male and 3 female flies. These were then flipped into new vials every 24 
hours with the aim of getting a comparable number of eggs laid in each vial. At 2 
days of larval development the 6 vials with most comparable larval activity from each 
genotype were chosen and had 500 μl of one of the compounds applied in a 500mM 
and 200mM concentration with each repeated in triplicate. This resulted in final 
concentrations of approximately 25mM and 10mM once diluted by the food. Controls 
were also setup for each compound using 500 μl of the solvent in which the 
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compound was diluted. The only exception to this protocol was carbamazepine which 
does not dissolve well in any solvent which can be applied to drosophila. Therefore 
this was applied as a partial suspension in 50% ethanol as this was the strongest 
solvent which was determined not to have a significantly negative impact on the 
larvae. 
Ten days after egg laying counts were taken of the number of flies hatched in each 
vial, this allowed for a quick determination of which compounds had an effect and 
were worth repeating. Flies from this initial count were also kept to use for further 
phenotypic study to assess whether any of the compounds had a significant effect of 
the size of the flies.
This protocol was repeated for the compounds ethosuximide, propanolol and 
carbamazepine based on the results of the preliminary trials. On the repeated trial 
the number of flies hatched at day 10 were counted and removed from the vials and 
further counts were carried out on days, 12, 14, 16 and 18 to look for signs of 
developmental delay (Fig 2.1). 
Figure 2.1 - Experimental timeline for application of compounds and counting of 
hatched flies.
Compound Assay - with set number of embryos
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The results from the second compound assay showed some interesting findings, 
however the results for developmental delay were shown to be very unreliable due to 
variation in the number of eggs laid in each vial. This was particularly notable in the 
cap 1 & 2 double mutants which appeared to lay very unreliably. To combat this a 
final assay was set up using 50 embryos per vial rather than trusting every fly to lay 
an average number in a vial. This was carried out using the method previously 
described for embryo collection for the nutrition trials. 
In the same way as the previous assays compounds were applied to the day 2 larvae 
produced from the embryos. In this final trial the compounds were applied in a wider 
range of concentrations to achieve results appropriate for the creation of dose 
response curves (Table 2.5). Counts of hatched flies were then carried out on day 10, 
12, 14, 16 and 18 and flies disposed of after each count. 
Table 2.5 - Compounds and concentrations used in final trials showing both 
concentration before addition to food and afterwards.
Compound Initial Concentrations
(before application to 
food)
Final Concentrations 
(after application to 
food)
Ethosuximide 1.25M, 0.5M, 0.2M, 
0.08M
62.5mM, 25mM, 10mM, 
4mM
Propranolol 0.5M, 0.2M, 0.08M 25mM, 10mM, 4mM




Total Adult Fly Emergence
Trials were carried out to ascertain the effects of various types of nutrient deprivation 
on cap methylation mutant drosophila. For the purposes of simplifying the annotation 
in the results, the genotypes will be described as follows, C or control (Yellow White 
Mutant),  Cap1null (yw CG6379null), Cap 2null (aftnull) and  Cap 1null Cap 2null (yw 
CG6379null; aftnull). The first results to consider are the overall number of flies 
emerging over the 18 day period from egg laying. The control flies showed a 
reduction in numbers in all nutrient restriction conditions when compared to normal 
food. The most reduction was seen in the reduced yeast conditions at 20% and 2% 
yeast with only 40% of the flies reaching adult hood. The Cap1null mutants showed 
very little variation in emergence across all food types except on the 2% yeast food 
where only a small percentage emerged. The Cap2null mutants also showed a similar 
pattern with little variation between food types except for the 2% yeast food where 
none emerged (fig 3.1). Finally the Cap1null Cap2null mutants showed a reduction in 
emergence on all food types, however interestingly remained at a similar level to the 
control on the 2% yeast food.
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Figure 3.1 - Total percentage of adult flies emerging from 50 embryos in an 18 day 
period after egg laying. Comparing nutrient restricted food types to cap methylation 
mutant genotypes. There were no survivors for the Cap2null flies on Y2% food. Error 
bars show standard deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 
2null - aftnull and  Cap 1null Cap 2null (CG6379null; aftnull).
Developmental Delay
Comparison of the time taken for flies to emerge was also carried out, counting the 
flies at 2 day intervals to look for any developmental delay. As expected on standard 
food the majority of flies emerged on day 10 for all genotypes and after day 12 no 
more flies emerged. There was however a significantly smaller percentage of flies for 
the Cap1null mutants which showed a smaller number on day 10 and a slightly larger 
number emerging on day 12 (fig 3.2a). The food with an absence of sugar (dextrose) 
also showed a similar pattern with the majority of flies hatching on days 10 and 12. It 
does however show a developmental delay particularly in Cap1null and Cap12null  
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mutants with a greater percentage of flies emerging on day 12 (fig 3.2d). All other 
food types have a reduction in the amount of yeast supplied at 40%, 20% and 2%, 
which show no emergence of flies at 10 days in any genotype. These results also 
appear to show that the greater the reduction in yeast the greater the developmental 
delay and the smaller overall percentage of flies emerge by day 18. This is 
particularly notable in the 2% yeast food where no emergence is seen in Cap 2null 
and only 2% in Cap 1null. Interestingly however the Cap 1null Cap 2null mutant doesnʼt 
show any reduction compared to the other 2 yeast reduced food types.
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Figure 3.2 Developmental delay graphs showing emergence of adult flies from 50 
embryos over an 18 day period from egg laying on nutrient restricted food types. a) 
Normal food, b) yeast reduced to 20 %, c) yeast reduced to 2%, d) no dextrose, e) all 
nutritional constituents reduced to 40%. C - Yellow White Mutant, Cap1null  - 
CG6379null, Cap 2null  - aftnull and  Cap 1null Cap 2null  - yw CG6379null; aftnull.
Negative Geotaxis - Motor Control
Negative geotaxis was carried out on the flies from each food type to establish 
whether there was any locomotor dysfunction. This was not possible on any cap1null 
cap2null mutants except standard food and only on the control flies for 2% yeast as 
not enough of the emerging flies were surviving by the point at which negative 
geotaxis was carried out. The least reduction in motor ability occurred in cap 1null 
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females across all analysed food type. Interestingly the motor ability of all mutants 
appears to increase under 20% yeast conditions (Fig. 3.3). The male flies show a 
very similar pattern to the females suggesting little difference between gender.
Figure 3.3 - Negative geotaxis performance index for female and male cap mutant D. 
melanogaster on nutrient reduced food types. Error bars show standard deviation. 
The genotypes not assayed due to lack of flies were Cap1null Y2%, Cap2null Y2% and 
Cap12null F40%, S0,Y2% and Y20%.  F - Normal food, Y20% - yeast reduced to 20 
%, Y2% - yeast reduced to 2%, S0 - no dextrose, F40%  - all nutritional constituents 
reduced to 40%. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - aftnull and  
Cap 1null Cap 2null  - CG6379null & aftnull.
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Developmental Restriction - Body Size
Measurement of body size was also carried out on flies from each genotype and food 
type with the exception of Cap 1null and Cap 2null on the 2% yeast food and Cap 1null 
Cap 2null on the 20% yeast food. Measurements on these flies could not be carried 
out either because no flies emerged or a very limited number emerged. Flies were 
measured by means of fixing to a microscope slide and then measuring a straight 
line from the head to the end of the abdomen (Fig 3.4) Once standard deviation was 
taken into account there was very little significant difference between genotypes and 
food types (Fig 3.5). Analysis was also carried out on total numbers across all 
genotypes on each food type, this also showed no significant differences between 
the food types (Fig. 3.6).
Figure 3.4 - Example of body length measurement technique of D. melanogaster
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Figure 3.5 - Sizes of D.melanogaster cap mutant flies on reduced nutrient food types. 
Error bars show standard deviation. Assays were not carried out on Y2% Cap1null and 
Cap2null  and Y20% Cap12null due to a lack of surviving flies. F - Normal food, Y20% - 
yeast reduced to 20 %, Y2% - yeast reduced to 2%, S0 - no dextrose, F40%  - all 
nutritional constituents reduced to 40%. C - Yellow White Mutant, Cap1null - 
CG6379null, Cap 2null - aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Figure 3.6 - Average size across all mutant genotypes on each nutrient restricted 
food type. Error bars show standard deviation. F - Normal food, Y20% - yeast 
reduced to 20 %, Y2% - yeast reduced to 2%, S0 - no dextrose, F40%  - all 






















The compound trials used a selection of ion channel blockers to look for effects of 
mRNA cap methylation on neural development. Ion channels were blocked  and the 
phenotypic effects of this studied in each genotype. 
The experimental procedure had three stages, preliminary trials using a large number 
of compounds, followup trials with the compounds showing a potential phenotypic 
effect and finally trials using a defined number of embryos.
Preliminary Trials
A preliminary trial was carried out to establish any variation in the effect of a range of 
compounds between the different genotypes (Fig 3.7). Controls were also put in 
place using the solvents in which the compounds were diluted. The first result to 
consider is that a significantly smaller number of the Cap 1null Cap 2null mutants 
emerged under all compound conditions including H2O suggesting that the results for 
these mutants may not be accurate to compare to other genotypes. GABA and 
Acetylcholine appeared to have little effect when compared to the H2O control in all 
genotypes and increased concentration of these compounds didnʼt show a significant 
reduction survival.
From the preliminary trial 3 compounds were chosen for further trials based on their 
significant overall effect of survival rates in all genotypes and interesting increase in 
survival rate of some genotypes over the control. The first of these was Ethosuximide 
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which at 10mM concentration showed a greater number of Cap 2null mutants hatching 
compared to Cap 1null mutants. However when the concentration was increased to 
25mM the Cap 2null mutants dropped off and the Cap 1null mutants increased. Both 
carbamazepine and propranolol were also chosen as they were shown to have a 
significant impact on the number of flies emerging and a significant discrepancy 
between the control genotype and the cap mutant genotypes. Some interesting 
results were also seen in GABA, flunarizine and acetylcholine however these would 
require further trials to assess their true effect (fig. 3.7).
Figure 3.7 - Trial of D.melanogaster mRNA cap methylation mutants with various 
compounds applied to larvae, 2 days post egg laying. C - Yellow White Mutant, 
Cap1null - CG6379null, Cap 2null - aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
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Follow-up Compound Trials
The results of the followup trials were first analysed by dose response, to ascertain 
the effect of increasing concentration of each compound on the flies. The Cap 1null 
and Cap 1null Cap 2null larvae treated with ethosuximide both showed a reduction in 
the overall number of flies emerging as the concentration increased. However the 
control and Cap 2null flies both showed an increase suggesting that ethosuximide 
may promote growth and survival in these flies (fig. 3.8a). This however is not 
supported by the preliminary trials which showed the opposite result (fig. 3.7). 
Figure. 3.8 - Percentage emergence of mRNA cap mutant D.melanogaster treated 
with varying concentrations of the ion channel blocking compounds a) Ethosuximide. 
b) Propranolol c) Carbamazepine. C - Yellow White Mutant, Cap1null  - CG6379null, 
Cap 2null  - aftnull and  Cap 1null Cap 2null -CG6379null & aftnull.
The flies hatching from larvae treated with propranolol showed a decrease in 
percentage emerging for all genotypes, however Cap 1null Cap 2null mutants showed a 
more gradual decline than the other mutants or the control, which suggests a 
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possible significant interaction when no additional cap methylation is present (fig. 
3.8b).
Carbamazepine unfortunately couldnʼt be trialed at the same concentrations as the 
other compounds as it does not dissolve sufficiently in any solvent suitable for use 
with drosophila. It was applied in a 50% ethanol solution which resulted in a 
proportion of it dissolving. It was therefore applied as a suspension of approximately 
12.5mM. This showed a clear effect on all genotypes with the Cap 1null mutants being 
most effected and the control flies being least effected (fig. 3.8c). 
A comparison of developmental delay (late emergence) was also attempted which 
showed some potentially significant results, however, once standard deviation was 
calculated this removed any significance of these results. It is thought that the error 
was probably introduced as a result of the experimental method, relying on the flies 
within each vial to lay a comparable number of eggs on a daily basis. This was 
particularly noted as a problem with the Cap 1null Cap 2null mutants which showed 
much reduced fertilised egg production in all  trials. This was also mirrored in the 
results of the preliminary trials (Fig 3.9). 
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Figure 3.9 - Number of mRNA cap mutant D.melanogaster treated with 25mM 
Ethosuximide hatching over  period up to 18 days from initial egg laying. Error bars 
show standard deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - 
aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
In an attempt to rectify this problem and reduce the error a final set of trials were 
carried out, placing 50 embryos in a vial to ensure identical starting numbers before 
treatment with compounds. 
Compound Trials using a Defined Number of Individuals
The results of the final compound trials were analysed for dose-response as a much 
larger range of concentrations had been used, particularly with ethosuximide. The 
control flies showed a similar result to the previous trials with a slight increase in the 
percentage hatching between 0mM and 10mM and then a gradual drop as the 
concentration increases. The mutant flies however did not respond in a similar way to 
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the previous trial, Cap 1null mutants followed a similar pattern to the control flies 
whereas in the previous trial they had not shown this rise in hatching in the presence 
of the compound. Cap 1null Cap 2 null mutants also showed a similar pattern with an 
increase in hatching up to 10mM before rapidly falling off. This however is seen at a 
much smaller overall percentage emergence than the control and cap 1null mutants 
(Fig 3.10a).
Figure 3.10 - Average percentage emergence from 50 mRNA cap mutant 
D.melanogaster embryos treated with varying concentrations of the ion channel 
blocking compounds a) Ethosuximide b) Propranolol and c) Carbamazepine. C - 
Yellow White Mutant, Cap1null  - CG6379null, Cap 2null  - aftnull and  Cap 1null Cap 2null - 
CG6379null & aftnull.
Increasing propranolol concentration appeared to show a similar decline in flies 
emerging across all genotypes as concentration increases. The only exception to this 
is that in a similar way to ethosuximide concentration the cap 2null mutant falls off 
more rapidly on introduction of the compound than any others (Fig 3.10b).
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The final compound in these trials was carbamazepine, in a similar way to the 
pervious trials this had to be tested at a smaller range of concentrations due to the 
use of a suspension rather than a dissolved solution. The solvent used with 
carbamazepine was 50% ethanol solution which explains the more widely varied and 
reduced hatching in all genotypes at 0 mM carbamazepine concentration. The results 
also show a potential anomaly with no flies emerging in any genotype at 1.6mM 
concentration yet flies emerging in all but one genotype at 4mM (Fig 3.10c). It should 
however be noted that the very low percentage of overall emergence limits the 
reliability of these results.
Due to the increased accuracy which could be achieved by controlling the initial of 
number embryos it is possible to analyse graphs of developmental delay for each 
genotype. The most significant results of this analysis can be seen in flies treated 
with ethosuximide, at 4mM there is a clear developmental delay shown in Cap 1null 
Cap 2null mutants with no flies emerging until day 12 and at this point only a 
comparable number to other genotypes at day 12 (Fig 3.11 a). The most significant 
difference when the concentration is increased to 10mM is the reduction in Cap 2null 
mutants. At this point the control flies also come in line with the emergence pattern of 
cap 1null mutants (Fig. 3.11 b). At 25mM there is a clear developmental delay in all 
genotypes with cap 2null and Cap 1null Cap 2null having a slightly greater delay than the 
other genotypes (Fig. 3.11 c).
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Figure 3.11 - Number of mRNA cap mutant D.melanogaster hatching over period up 
to 18 days from initial egg laying after treatment with the ion channel blocking 
compound ethosuximide. a) 4mM, b) 10mM, c) 25mM Error bars show standard 
deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null - aftnull and  Cap 
1null Cap 2null - CG6379null & aftnull.
Propranolol was only analysed at 4mM for developmental delay due to the very small 
number of flies emerging at higher concentrations. All genotypes showed a 
comparable drop from the initial number of flies emerging at day 10 suggesting its 
only effect at this concentration is to reduce the overall number of flies rather than 
induce a developmental delay effect (Fig. 3.12).
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Figure 3.12 - Number of mRNA cap mutant D.melanogaster treated with 4mM 
propranolol hatching over period up to 18 days from initial egg laying. Error bars 
show standard deviation. C - Yellow White Mutant, Cap1null - CG6379null, Cap 2null 
aftnull and  Cap 1null Cap 2null - CG6379null & aftnull.
Preliminary Cap 1null Cap 2null Breeding Trials
Following the observation that Cap 1null Cap 2null mutants didnʼt produce as many 
adult flies as the other mutants a preliminary trial was setup to assess the fecunduity 
of these flies. An initial trial was set up with mutant virgin females and control males. 
This trial suggested a potential mating deficiency in these flies as in a 2 hour period 
only one out of the 10 flies mated. Further study would be required to confirm this 




- Nutrient restriction reduces overall number of flies emerging.
- Yeast reduction has the most significant effect.
- Cap 2null mutants overall suffer least from nutrient deprivation except at 2% yeast.
- Absence of both Caps simultaneously however seems to rescue these nutrient 
deprived flies
- Removal of dextrose from food resulted in a slight developmental delay in Cap 1null 
and Cap 1null Cap 2null mutants.
- Decreasing yeast concentration increases developmental delay in Cap 1null and Cap  
2null mutants but not Cap 1null Cap 2null
- 20% yeast appears to increase motor ability in negative geotaxis
- No significant effect was found on body size of any genotype on any food type.
Compound Trials
- Ethosuximide
- Preliminary trials showed a fall in the number of Cap 2null mutants with 
increase in concentration but an increase in Cap 1null mutants.
- These initial results were contradicted by the follow-up trial. 
- The final results however show much closer alignment with the preliminary 
trial results with a decrease in Cap 2null mutants with increase in 
concentration but an increase in Cap 1null mutants.
- The Cap 1null Cap 2null mutants also follow the same pattern as Cap 1null
- Increasing concentration results in developmental delay in all genotypes but 
is more pronounced in Cap 2null and Cap 1null Cap 2null mutants.
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- Propranolol
- All genotypes show a decrease with increasing concentration
- Cap 1null Cap 2null mutants show a more gradual decline in numbers 
compared to the other genotypes.
- Cap 2null mutants decline more quickly with increased concentration
- No sign of developmental delay
- Carbamazepine




The 7-methyl guanosine cap on the first nucleotide of mRNA has previously been the 
focus of much research. It has been shown to be one of the first modifications to the 
RNA strand in the mRNA pre-processing stage and is thought to be important in 
triggering the formation of the poly-a tail on the 3ʼ end of the mRNA strand. It has 
also been shown to be important for the protection of mRNA from degradation by 
endonucelases and initiation of translation through binding with the translation 
initiation complex (Soller, 2006). Studies of Cap 1 and 2 methylation, however, are 
much more limited as knockout organisms have not been described yet. It is however 
important to also note that studies have shown cap 1 methylation to be present on all 
mRNA strands in humans and to be specifically formed by some viruses suggesting 
that it must have an important role (Kruse, et al. 2011). It has been suggested in 
some research that the presence of cap 1 may increase translational efficiency and 
may also interact without proteins to suppress any immune response to the mRNA 
(Daffis, et al. 2010 & Belanger, et al. 2010). However there is  very limited 
understanding of the route by which this methylation acts to increase efficiency. 
Cap 2 methylation has undergone even less research than cap 1 and there is no 
current information to suggest what if any phenotypic effects this causes. As cap 2 
methylation is not present on all mRNA strands this would suggest that it is not 
essential for efficient translation, however, as it is formed by a specific 
methyltransferase enzyme and is present on approximately half of all mRNA which 
would suggest that it isnʼt simply an accidental addition (Belanger, et al. 2010 & 
Werner, et al. 2011).
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In an attempt to further define the role of cap 1 methylation and to identify a role for 
cap 2 methylation a series of trials were carried out focused on the effects of nutrient 
deprivation on these mutants. Nutrient deprivation is known to act on two pathways 
within cells, the insulin PI3 kinase pathway and the TOR (Target of Rapamycin) 
pathway (Li, et al. 2010). These pathways can act independently of each other or in 
conjunction with the insulin PI3 kinase running into the TOR pathway (Li, et al. 2010). 
Nutrient deprivation has now been shown in a number of studies to increase life span 
at a cost to developmental rate mainly through interactions in the TOR pathway 
(Layalle, et al. 2008). It is believed that amongst other control mechanisms this may 
be as a result of modification to the rate of translation which would result in slower 
production of proteins so a slower overall growth rate (Penney, et al. 2012). This may 
also have an effect on synaptic homeostasis and plasticity as reduced translational 
rates slow the ability for increases in the number of post-synaptic receptors and 
effect the retrograde control of neurotransmitter release (Penney, et al. 2012). As cap  
1 methylation has been shown to influence translational efficiency this is a good initial 
model as theoretically the presence of cap 1 methylation should partially rescue the 
nutrient deprived flies in comparison to those with no cap 1 methylation. 
The initial results for these trials were focused on overall emergence of flies from 
each genotype on each food type. Although this does not show delayed development 
it can be used to assess complete limitation of development. On standard food all 
genotypes showed a similar percentage emergence of around 68% with the 
exception of the cap 1null mutant which only showed emergence of 44%. This would 
immediately suggest a developmental problem induced by the absence of cap 1 
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methylation, however, this is not then reflected in Cap 1null Cap 2null mutants. This 
result is also supported by the developmental delay analysis which shows slightly 
slower emergence of the cap 1null mutants compared to the other genotypes. This 
would almost suggest that the presence of cap 2 methylation on its own is a limiting 
factor for translation. This finding also appears to be supported in the 20% yeast food 
type, which shows an absence of cap 1 methylation results in delayed development 
compared to the control flies. An absence of cap 2 results in an initial delay in 
development followed by an increase in developmental rate above the control flies, 
however, this is again contradicted by the double mutant genotype. 
The cap 1 methylation effects in this study can be compared to pervious studies to 
help ascertain the reliability of the results. Although there are no other studies which 
have used nutrient deprivation, Kuge, et al. (1998) showed that the rate of translation 
was increased in the presence of cap 1 methylation and therefore should result in 
developmental delay and potentially reduced numbers emerging as adults. This 
supports the finding that on standard food the cap 1null mutant has reduced numbers 
and slightly delayed development. There is also some evidence from crystallographic 
analysis that cap 1 methylation may strengthen binding to eIF4E (Kruse, et al. 2011). 
The effect of the absence of cap 2 methylation is much harder to define. When 
compared to control flies on all nutrient reduced food types a significantly increased 
developmental rate is seen. This is quite unexpected as it can be assumed that all of 
these mutants would have cap 1 methylation which would imply a limiting effect of 
cap 2 methylation, however, there is currently no evidence as to how this functions. It 
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was suggested by Belanger, et al. (2010) that as removal of cap 1 methylation had 
only very limited effect but removing both cap 1 and 2 methylation may have a more 
obvious phenotypic effect. It is clear from the results that the double mutant flies do 
respond differently to those with methylation. Notably they tend to have slightly 
slower and reduced development with nutrient restriction, however when the level of 
yeast is reduced to 2% the decrease in flies emerging is marginal in comparison to 
the other mutants. This again may support the theory of cap 2 methylation slowing 
the rate of translation. 
To understand the effect of the different food types it is important to understand how 
the different nutrients are used by the Drosophila and their potential effect. It has 
been shown by Bass, et al. (2007) that in terms of life span the need for sugar is very 
limited and above 50g/l of sucrose in food the flies do not modify their eating 
behaviour but still undergo fecundity reduction suggesting a toxic effect of high sugar 
concentration. This study uses dextrose as the sugar source as this reduces bacterial 
growth, however, it is assumed that this will have the same effect on flies as sucrose 
(Ashburner & Roote, 2007). Previous studies have shown that yeast has the main 
dietary restriction effect when it comes to increased life span and that is reflected in 
this study with the slowing of development alongside reduction is yeast concentration 
in food (Chippindale, et al. 2002). It has also been shown that the effects of yeast are 
not related to caloric provision but the quality of yeast used and its nutritional 
composition (Ashburner & Roote, 2007). Grandison, 2009 has shown that the 
nutritional component within yeast which has this effect on lifespan and development 
is amino acid content and that other components have little effect on life span. This 
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also supports the theory that dietary restriction would interact with the TOR pathway 
as this is very sensitive to amino acid intake and therefore potentially translational 
initiation efficiency (Grandison, 2009).
This evidence supports the results that decreasing yeast concentration in food would 
result in more developmental delay for cap 1null mutants if cap 1 influences translation 
efficiency as some studies suggest. As developmental delay is also induced in cap 
2null mutants this may suggest that they also have a role in translational efficiency. 
However this is not supported by the results of the Cap 1null Cap 2null mutants who 
appear to be less effected by the reduced yeast than the other genotypes except the 
control. This may either imply an experimental error or some unknown reaction 
resulting for the absence of any cap methylation. 
The analysis of body size of the nutritionally deprived flies showed very little 
significant variation between genotypes on each food type. Layalle, et al. (2008) 
suggest that reduced nutrition results in overall larger flies due to an increased 
growth period this is not reflected in the results of the current study. The reason for 
this may however be related to the inherent problems of measuring full body length of 
flies, there is potential for the flies body shape to be curled or contracted which when 
looking for a small amount of variation introduces a greater margin of error. A more 
accurate strategy may have been to measure head capsule width as although this 
varies less than full body size it is possible to carryout much more accurate 
measurement.
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Negative geotaxis assays were carried out to establish any motor dysfunction within 
the dietary restricted cap methylation flies. Due to the relationship previously 
described between the homeostatic control at synapses and translational efficiency 
this should demonstrate the influence of cap methylation on translational efficiency. It 
would be expected that if cap 1 or 2 methylation increased efficiency that at a 
restricted level of yeast those flies with cap methylation would perform better. This 
however is not reflected in the results as at 20% yeast all genotypes performed better 
particularly the Cap 1null mutants. This may be a reflection of a toxicity effect of the 
higher concentration of yeast in the standard food and not related to the dietary 
restriction (Ashburner & Roote, 2007). Unfortunately at 2% yeast concentration the 
number of flies emerging was reduced below the number required for negative 
geotaxis so analysis of this effect at a lower concentration can not be carried out. 
Further research to look at a wider range of yeast concentrations on cap mutants 
may resolve the reason for this effect.
The other trials carried out looked more specifically at neural and synaptic 
development of cap methylation mutants through treatment with compounds known 
to effect neural and synaptic signalling. Synaptic plasticity has been shown to have a 
strong link to translational efficiency potentially through regulation at the mRNA 
processing stage, post-transcription (Costa-Mattiolo, et al. 2009). Synapses use 
either G-protein-coupled receptors or ionotropic receptors to sense neurotransmitter 
release (Voglis & Tavernarakis, 2006). By introducing an ion-channel blocking 
compound onto the larvae this would theoretically mean that development would be 
slow or halted in those mutants which had less efficient translation to produce extra 
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ion channels and restore homeostasis. The initial range of compounds in preliminary 
trials also included acetylcholine a neurotransmitter to look for any effects of this 
destabilising synaptic homeostasis. 
The preliminary trial showed some interesting results, firstly it should be noted that 
the accuracy of results related to the double mutant (Cap 1null & Cap 2null) are very 
poor in the preliminary trial due to their unreliable mating and laying of fertilised eggs, 
this can be seen particularly in those flies treated with H2O which should have had 
very little effect. The preliminary trial also only accounts for flies hatched on day 10 
so does not show any flies which may have been developmentally delayed and 
hatched at a later point. 
The compound ethosuximide appears to have a more significant effect on some 
genotypes than others, in both the preliminary and final trials those genotypes with 
an absence of cap 2 methylation were most greatly effected by the compound. 
Ethosuximide is an ion channel blocker which works on a wide range of ion channels 
but particularly T-type calcium channels (Collins, et al. 2008). T-type calcium 
channels are known to be very sensitive and are the first ion channels to respond to 
weak stimulus (Cain & Snutch, 2010). This would suggest that the effect of inhibiting 
a number of these channels would result in a decrease of response to weak stimulus 
within the neurones. There is an apparent interaction between cap 2 methylation and 
the effects of this compound as greater developmental delay was seen in cap 2null 
and Cap 1null Cap 2null flies. This may suggest that cap 2 has involvement in 
increasing the efficiency of the translation process, however, this is contradicted by 
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the results from the  nutrient restricted flies. The alternative explanation for this is that 
cap 2 methylation or ethosuximide has some other unknown interaction which 
generates this effect.
Propranolol another trialed compound, is a non-selective beta blocker, blocking 
adrenergic g-protein coupled receptors (Dzialowski, et al. 2006). Propranolol acts to 
block the g-protein coupled rectors in synapses which is the root cause of any 
developmental effects related to cap methylation. This explains the overall decrease 
in the emergence of flies with increasing concentration of propranolol. It would again 
be expected that if cap methylation promoted translational efficiency that those flies 
without cap methylation would experience more effect than those with. The results 
also support a role for cap 2 methylation in the translation process as cap 2null 
mutants were most greatly effected by the increasing concentration of propranolol. 
Propranolol, however, did not show any developmental delay for any genotype, 
suggesting that the inhibition of adrenergic g-protein coupled receptors above a 
certain level can not be corrected by synaptic homeostasis processes. 
The final compound carbamazepine is known to block the functioning of voltage 
gated sodium channels which are often present in synapses (Sheets, et al. 2008). 
The results for this compound appear very unreliable, the root cause of this is two-
fold, partially as a result of the compounds inability to dissolve in water and partially 
due to the effects of the ethanol solution used as a solvent. Even when applied as a 
suspension in 50% ethanol solution carbamazepine becomes very sticky and it is not 
possible to accurately distribute an exact concentration to vials. Along with this the 
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high level of ethanol required also has an adverse effect on the flies as seen in the 
significant reduction in control fly hatching in all genotypes. It is, however, an 
interesting result that the ethanol solution appeared to have an interaction between 
the genotypes with those having the cap 2 methylation in place being more 
successful than those without. This may suggest a protective role of cap 2 
methylation in the presence of toxic levels of compounds such as ethanol. This is an 
area which would benefit from further study. 
There is suggestion from studies of viruses that cap 1 methylation interacts with 
interferon induction which has an anti viral role in cells (Daffis, et al. 2010). It is 
suggested that this is the reason for viruses which encode their own methyltranferase 
enzymes to produce this methylation as it prevents  the release of interferons as part 
of an immune response to foreign RNA. If this is the case this suggests an entirely 
different pathway by which cap methylation could be influencing translation rather 
than just simply through the efficiency of binding. It should, however, also be noted 
that this is less likely to be a root of action for cap 2 methylation as it doesnʼt occur on 
all mRNA and viruses do not encode their own cap 2 methyltransferases although 
can use those already present within the cell (Kruse, et al. 2011).
There are a number of problems within this study which have put the reliability of 
some results into doubt. As mentioned above the compound carbamazepine could 
not be applied accurately and if a new method for the application of this compound 
could be developed then this may show more significant and reliable results. An 
ongoing issue in the initial compound trials was the unreliability of egg laying 
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particularly by the Cap 1null Cap 2null mutants. This was rectified in later trials and it is 
important to note that the use of specific numbers of embryos in future studies would 
significantly reduce error in the results. It should also be noted that all of the 
compounds used have a significant number of reported effects which are often 
subject to limited study and not well understood. This means that caution should be 
taken when using them to directly look for effects of cap methylation on translation 
efficiency as other chemical interactions may also be taking place. Further study is 
also required into the breeding of Cap 1null Cap 2null mutants as preliminary findings 
suggest that they may have a breeding deficiency, which if studied further may 
demonstrate a further role of cap 1 and 2 methylation.
There are, however, some interesting findings from this study which have potential to 
generate further research. Some of the results within the study seem to backup 
theories that cap 1 methylation may cause a slight increase in translational efficiency. 
It also opens up some interesting avenues for further study into the role of cap 2 
methylation as in the nutritional trials, this appeared to have a limiting effect on 
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F Day 10 Day 12 Day 14 Day 16 Day 18 Total
C1 34 2 0 0 0 36
C2 27 2 0 0 0 29
C3 31 5 0 0 0 36
PC1 1 14 7 0 0 0 21
PC1 2 9 13 0 0 0 22
PC1 3 15 9 0 0 0 24
PC2 1 28 4 0 0 0 32
PC2 2 30 3 0 0 0 33
PC2 3 25 9 0 0 0 34
PC12 1 25 4 0 0 0 29
PC12 2 36 2 0 0 0 38
PC12 3 29 4 0 0 0 33
Y20%
C1 0 23 0 0 0 23
C2 0 18 7 2 0 27
C3 0 0 23 5 0 28
PC1 1 0 0 5 13 5 23
PC1 2 0 17 5 2 0 24
PC1 3 0 0 5 17 3 25
PC2 1 0 9 14 5 0 28
PC2 2 0 1 16 7 2 26
PC2 3 0 3 19 12 0 34
PC12 1 0 0 4 16 2 22
PC12 2 0 0 1 9 3 13
PC12 3 0 0 1 5 6 12
Y2%
60
C1 0 0 13 9 0 22
C2 0 0 3 14 3 20
C3 0 0 12 6 0 18
PC1 1 0 0 0 0 3 3
PC1 2 0 0 0 0 0 0
PC1 3 0 0 0 0 2 2
PC2 1 0 0 0 0 0 0
PC2 2 0 0 0 0 0 0
PC2 3 0 0 0 0 0 0
PC12 1 0 10 9 2 0 21
PC12 2 0 3 9 12 4 28
PC12 3 0 1 10 2 0 13
S0
C1 19 4 0 0 0 23
C2 22 7 0 0 0 29
C3 24 7 0 0 0 31
PC1 1 12 9 1 0 0 22
PC1 2 10 10 2 0 0 22
PC1 3 11 18 1 0 0 30
PC2 1 24 7 0 0 0 31
PC2 2 29 5 0 0 0 34
PC2 3 26 8 0 0 0 34
PC12 1 2 24 1 0 0 27
PC12 2 6 14 1 2 0 23
PC12 3 5 10 0 1 0 16
F40%
C1 0 28 4 0 0 32
C2 0 22 5 0 0 27
C3 2 21 1 0 0 24
PC1 1 0 15 6 0 0 21
PC1 2 0 13 8 0 0 21
61
PC1 3 0 12 11 0 0 23
PC2 1 0 22 14 2 0 38
PC2 2 0 21 7 2 0 30
PC2 3 0 26 5 2 0 33
PC12 1 0 5 13 1 0 19
PC12 2 0 1 15 2 0 18




Genotype Gender Above Below Total P
F C F 6 3 15 0.6
F C F 6 4 15 0.566667
F C F 3 2 15 0.533333
F C M 8 0 15 0.766667
F C M 5 3 15 0.566667
F C M 5 2 15 0.6
F PC1 F 9 1 10 0.9
F PC1 F 6 1 10 0.75
F PC1 F 4 0 10 0.7
F PC1 M 3 1 10 0.6
F PC1 M 6 1 10 0.75
F PC1 M 6 1 10 0.75
F PC12 F 0 9 10 0.05
F PC12 F 0 10 10 0
F PC12 F 0 10 10 0
F PC12 M 0 9 10 0.05
F PC12 M 0 8 10 0.1
F PC12 M 0 9 10 0.05
F PC12 M 0 9 10 0.05
F PC12 M 0 10 10 0
F PC12 M 0 10 10 0
F PC2 F 2 4 10 0.4
F PC2 F 1 3 10 0.4
F PC2 F 1 4 10 0.35
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F PC2 F 1 4 10 0.35
F PC2 F 0 7 10 0.15
F PC2 F 2 7 10 0.25
F PC2 F 0 5 10 0.25
F PC2 F 0 5 10 0.25
F PC2 F 0 4 10 0.3
F PC2 M 0 2 10 0.4
F PC2 M 0 4 10 0.3
F PC2 M 0 5 10 0.25
F PC2 M 0 6 10 0.2
F PC2 M 0 5 10 0.25
F PC2 M 1 6 10 0.25
F PC2 M 1 4 10 0.35
F PC2 M 2 2 10 0.5
F PC2 M 1 3 10 0.4
F40% C F 7 1 10 0.8
F40% C F 6 2 10 0.7
F40% C M 5 1 10 0.7
F40% C M 6 3 10 0.65
F40% C M 6 1 10 0.75
F40% PC1 F 7 2 10 0.75
F40% PC1 F 6 2 10 0.7
F40% PC1 M 5 3 10 0.6
F40% PC1 M 8 2 10 0.8
F40% PC1 M 2 5 10 0.35
F40% PC2 F 1 1 10 0.5
F40% PC2 F 1 1 10 0.5
F40% PC2 F 2 2 10 0.5
F40% PC2 M 2 5 10 0.35
F40% PC2 M 1 5 10 0.3
F40% PC2 M 1 6 10 0.25
F40% PC2 M 2 4 10 0.4
F40% PC2 M 4 1 10 0.65
F40% PC2 M 4 1 10 0.65
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S0 C F 5 1 10 0.7
S0 C F 5 2 10 0.65
S0 C F 4 1 10 0.65
S0 C M 3 2 10 0.55
S0 C M 3 3 10 0.5
S0 C M 4 0 10 0.7
S0 PC1 F 9 0 10 0.95
S0 PC1 F 7 1 10 0.8
S0 PC1 F 7 1 10 0.8
S0 PC1 M 2 2 10 0.5
S0 PC1 M 4 2 10 0.6
S0 PC2 F 1 2 10 0.45
S0 PC2 F 1 3 10 0.4
S0 PC2 F 0 5 10 0.25
S0 PC2 F 3 1 10 0.6
S0 PC2 F 1 1 10 0.5
S0 PC2 F 1 2 10 0.45
S0 PC2 F 3 1 10 0.6
S0 PC2 F 3 0 10 0.65
S0 PC2 F 1 1 10 0.5
S0 PC2 M 0 7 10 0.15
S0 PC2 M 2 7 10 0.25
S0 PC2 M 0 6 10 0.2
S0 PC2 M 1 7 10 0.2
S0 PC2 M 0 7 10 0.15
S0 PC2 M 0 6 10 0.2
S0 PC2 M 1 6 10 0.25
S0 PC2 M 0 7 10 0.15
S0 PC2 M 0 6 10 0.2
Y2% C F 6 3 10 0.65
Y2% C F 5 1 10 0.7
Y2% C M 6 0 10 0.8
Y2% C M 8 0 10 0.9
Y20% C F 6 0 10 0.8
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Y20% C F 9 0 10 0.95
Y20% C F 6 1 10 0.75
Y20% C M 5 1 10 0.7
Y20% C M 8 0 10 0.9
Y20% PC1 F 9 1 10 0.9
Y20% PC1 F 8 0 10 0.9
Y20% PC1 F 9 0 10 0.95
Y20% PC1 M 7 0 10 0.85
Y20% PC1 M 9 0 10 0.95
Y20% PC2 F 6 0 10 0.8
Y20% PC2 F 4 0 10 0.7
Y20% PC2 F 6 1 10 0.75
Y20% PC2 F 5 1 10 0.7
Y20% PC2 F 6 1 10 0.75
Y20% PC2 F 3 2 10 0.55
Y20% PC2 M 6 1 10 0.75
Y20% PC2 M 7 0 10 0.85
Y20% PC2 M 6 1 10 0.75
Y20% PC2 M 4 0 10 0.7
Y20% PC2 M 3 2 10 0.55
Y20% PC2 M 4 4 10 0.5
Compound trials with defined number of Individuals
Genotype Compound Day 10 Day 12 Day 14 Day 16 Day 18 Total
C 50% Ethanol 11 0 0 0 0 11
C 50% Ethanol 8 0 0 0 0 8
C 50% Ethanol 19 1 0 0 1 21
PC1 50% Ethanol 5 0 0 0 0 5
PC1 50% Ethanol 5 0 0 0 0 5
PC1 50% Ethanol 7 0 0 0 0 7
PC2 50% Ethanol 4 0 0 0 0 4
PC2 50% Ethanol 2 0 0 0 0 2
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PC2 50% Ethanol 0 0 0 0 0 0
PC12 50% Ethanol 0 0 0 0 0 0
PC12 50% Ethanol 0 1 0 0 0 1
PC12 50% Ethanol 0 0 0 0 0 0
C C1.6 0 0 0 0 0 0
C C1.6 0 0 0 0 0 0
C C1.6 0 0 0 0 0 0
PC1 C1.6 0 0 0 0 0 0
PC1 C1.6 0 0 0 0 0 0
PC1 C1.6 0 0 0 0 0 0
PC2 C1.6 0 0 0 0 0 0
PC2 C1.6 0 0 0 0 0 0
PC2 C1.6 0 0 0 0 0 0
PC12 C1.6 0 0 0 0 0 0
PC12 C1.6 0 0 0 0 0 0
PC12 C1.6 0 0 0 0 0 0
C C10 0 0 0 0 0 0
C C10 0 0 0 0 0 0
C C10 0 1 0 0 0 1
PC1 C10 0 0 0 0 0 0
PC1 C10 0 0 0 0 0 0
PC1 C10 0 0 0 0 0 0
PC2 C10 2 2 0 0 0 4
PC2 C10 3 0 0 0 0 3
PC2 C10 0 0 0 0 0 0
C C4 0 0 0 0 0 0
C C4 0 0 1 0 0 1
C C4 0 1 0 0 0 1
PC1 C4 0 0 0 0 0 0
PC1 C4 0 0 0 0 0 0
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PC1 C4 0 0 0 0 0 0
PC2 C4 1 1 4 0 0 6
PC2 C4 2 1 1 0 0 4
PC2 C4 3 0 1 0 0 4
PC12 C4 0 3 3 0 0 6
PC12 C4 0 0 0 0 0 0
PC12 C4 0 8 0 0 0 8
C E10 32 3 0 0 0 35
C E10 34 3 0 0 1 38
C E10 19 17 5 1 0 42
PC1 E10 27 5 0 0 0 32
PC1 E10 35 2 0 0 0 37
PC1 E10 25 5 0 0 0 30
PC2 E10 3 6 0 0 0 9
PC2 E10 0 0 0 0 0 0
PC2 E10 9 3 0 0 0 12
PC12 E10 0 8 7 0 0 15
PC12 E10 0 0 0 0 0 0
PC12 E10 7 11 0 0 0 18
C E25 4 16 9 2 0 31
C E25 4 15 4 3 1 27
C E25 1 11 9 2 0 23
PC1 E25 8 8 0 0 0 16
PC1 E25 2 10 0 0 0 12
PC1 E25 11 13 0 0 0 24
PC2 E25 0 0 0 0 0 0
PC2 E25 2 1 0 0 0 3
PC2 E25 0 5 5 2 0 12
PC12 E25 0 0 0 0 0 0
PC12 E25 0 0 1 0 0 1
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PC12 E25 0 0 2 0 0 2
C E4 40 0 0 0 0 40
C E4 36 0 0 0 0 36
C E4 31 8 0 0 0 39
PC1 E4 31 0 0 1 0 32
PC1 E4 25 0 0 0 0 25
PC1 E4 13 22 0 1 0 36
PC2 E4 26 6 2 0 0 34
PC2 E4 28 8 0 0 0 36
PC2 E4 12 0 0 0 0 12
PC12 E4 0 4 1 0 0 5
PC12 E4 0 13 0 0 0 13
PC12 E4 0 1 0 0 0 1
C E62.5 0 0 0 0 1 1
C E62.5 0 4 0 1 0 5
C E62.5 0 3 5 2 0 10
PC1 E62.5 0 0 0 0 0 0
PC1 E62.5 0 0 0 0 0 0
PC1 E62.5 0 0 0 1 0 1
PC2 E62.5 0 0 0 0 0 0
PC2 E62.5 0 0 0 0 0 0
PC2 E62.5 0 0 0 0 0 0
PC12 E62.5 0 0 0 0 0 0
PC12 E62.5 0 0 0 0 0 0
PC12 E62.5 0 0 0 0 0 0
C H2O 29 0 0 0 0 29
C H2O 38 0 0 0 0 38
C H2O 33 1 0 0 0 34
C H2O 31 0 0 0 0 31
C H2O 32 1 1 0 1 35
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C H2O 39 0 0 0 0 39
PC1 H2O 36 1 0 0 0 37
PC1 H2O 32 0 0 0 0 32
PC1 H2O 27 3 0 0 0 30
PC1 H2O 24 0 0 0 0 24
PC1 H2O 27 0 0 0 0 27
PC1 H2O 28 0 0 1 0 29
PC2 H2O 2 0 0 0 0 2
PC2 H2O 37 3 0 0 0 40
PC2 H2O 36 3 0 0 0 39
PC2 H2O 26 3 0 0 0 29
PC2 H2O 5 0 0 0 0 5
PC2 H2O 23 1 0 0 0 24
PC12 H2O 6 0 0 0 0 6
PC12 H2O 1 0 0 0 0 1
PC12 H2O 0 0 0 0 0 0
C None 39 0 0 0 1 40
C None 32 0 0 1 0 33
C None 38 0 0 0 0 38
PC1 None 22 1 0 0 0 23
PC1 None 25 2 0 0 0 27
PC1 None 25 0 0 0 0 25
PC2 None 18 1 0 0 0 19
PC2 None 43 0 0 0 0 43
PC2 None 43 1 0 1 0 45
C P10 1 11 5 0 0 17
C P10 2 10 2 0 0 14
C P10 4 7 3 0 4 18
PC1 P10 0 5 8 3 0 16
PC1 P10 0 0 1 0 0 1
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PC1 P10 0 2 1 0 0 3
PC2 P10 0 8 3 3 0 14
PC2 P10 0 3 1 0 0 4
PC2 P10 0 0 0 0 0 0
PC12 P10 0 0 1 0 0 1
PC12 P10 0 0 2 0 0 2
PC12 P10 0 0 0 0 0 0
C P25 0 0 1 0 0 1
C P25 0 1 0 0 0 1
C P25 0 2 1 0 1 4
PC1 P25 0 0 0 1 0 1
PC1 P25 0 0 0 0 0 0
PC1 P25 0 0 0 0 0 0
PC2 P25 0 0 0 0 0 0
PC2 P25 0 0 0 0 0 0
PC2 P25 0 0 0 0 0 0
PC12 P25 0 0 0 0 0 0
PC12 P25 0 0 0 0 0 0
PC12 P25 0 0 0 0 0 0
C P4 29 3 0 0 0 32
C P4 29 3 1 0 0 33
C P4 22 5 0 0 0 27
PC1 P4 25 4 0 1 0 30
PC1 P4 20 7 0 0 0 27
PC1 P4 11 0 0 2 0 13
PC2 P4 5 3 3 0 0 11
PC2 P4 15 4 1 0 0 20
PC2 P4 5 0 0 0 0 5
PC12 P4 0 0 0 0 0 0
PC12 P4 1 1 0 0 0 2
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PC12 P4 0 0 0 0 0 0
PC12 P4 0 0 0 0 0 0
PC12 P4 0 0 1 0 0 1
PC12 P4 0 2 0 0 1 3
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The LIM Domain Only (LMO) proteins have been shown to play a major role in 
cellular differentiation and development at the embryonic stage and in many human 
cancers. There is a large amount of evidence to show the crucial role of LMO2 within 
the early stages of hematopoiesis and due to the similarities of proteins in this family 
it would be logical to expect that LMO1 and LMO4 may also be involved. Current 
studies show that LMO1 has an involvement in some forms of T-ALL (T-Cell Acute 
Lymphoblastic Leukaemia) and LMO4 has a major role in cellular proliferation in 
some breast cancers. The aim of this study was to develop tools to perform 
overexpression and knockdown experiments with these proteins in murine early 
stage hematopoietic progenitors and in ES cells in an attempt to identify the function 
of the LMO1 and LMO4 proteins. Short Hairpin RNA (shRNA) constructs were 
produced and transfected into the cells and shown to work effectively in the 
knockdown of the proteins by up to 50%. Preliminary results regarding possible 
apoptotic effects of the LMO4 knockdown in myeloid progenitor cells were shown and 
a potential link to CDK9 suggested. This study provides the basis for future research 
into these proteins through the use of the tools created and starts to suggest possible 
roles for LMO1 and LMO4 in early stage hematopoiesis.
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Figure 5.1 Early hematopoetic development showing some of the cellular markers 
and transcription factors involved (Fehling et al. 2003, Lancrin, et al. 2009, Sturgeon, 
2013 & Gordon-Keylock&Medvinsky, 2011).
Figure 5.2. Similarities between the proteins in the LMO family (Modified from 
Matthews, et al. 2013).
Figure 6.1 Optimised PCR program for cloning of shLMO1 sequences.
Figure 6.2. qPCR Program for RNA expression analysis.
Figure 7.1. qPCR results comparing expression levels of LMO1, LMO2 and LMO4 to 
GAPDH on cDNA from cells at varying differentiation stages from the earliest stage 
ES cells (CCB and A2Lox) to Flk+ Hemangioblast type cells and finally myeloid 
progenitor cells (PUER) and differentiated progenitors.
Figure 7.2. Western blots using αLMO1, αLMO2 and αLMO1 antibodies on A2Lox 
ES cell nuclear extract (ES NE) and Flk+ cell nuclear extract (Flk+ NE). Flag LMO1 
and Flag LMO4 in PUER cells were also used as positive controls for LMO1 and 
LMO4. Confocal microscopy images show Flk+ ES cells stained for LMO1, LMO2 or 
LMO4 (Green) and DNA/DAPI showing the nucleus (RED). This shows LMO1 to be 
mainly cytoplasmic, LMO2 to be mostly nuclear and LMO4 to be both in Flk+ ES 
Cells.
Figure 7.3. Agarose gel image showing PCR products from shLMO1 and shLMO4 
reactions with pSM2C primers.
Figure 7.4. Digestions with BglII and MfeI of ligated shLMO1 and shLMO4 inserts 
after mini-preps. +ctrl shows the expected vector and insert sizes of positive clones, 
all clones showing an insert band of this size were regarded as positive.
Figure 7.5. PCR optimistation for cloning of the shLMO1 constructs. Products after 
digestion with EcoRI and XhoI.
Figure 7.6. a) Flow Cytometry analysis of plat-e cells co-transfected with an LMO1 
GFP expression construct and shLMO1 constructs (Red - shGFP, Green - shFF3, 
Blue - shLMO1 constructs). b) Flow Cytometry analysis of LMO1 GFP expressing 
PUER cells infected with shLMO1 constructs (Red - LMO1 GFP, Green - Uninfected 
cells, Blue - shLMO1 constructs.) 
Figure 7.7. Western blot showing protein extract from Plat-E cells (PE) and Plat-E 
cells transfected with over expression constructs for Flag-LMO1 (FLMO1) and Flag-
LMO4 (FLMO4).. Using both LMO and Flag primary antibodies to demonstrate the 
presence of both constructs and li-cor 800 secondary antibodies.
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Figure 7.8. Western blots showing LMO2, LMO4 and Flag antibodies on Flag-LMO2, 
Flag-LMO4 and PUER cell nuclear extract.
Figure 7.9. FACS plots for sorting of MigRI infected PUER cells and shLMO4 
infected PUER cells on days 1 and 5 post infection. The sorting uses a combination 
of FITC and PE detection to detect and sort the GFP positive cells. R3 shows the 
percentage of GFP positive cells present within the population. The gating on Day 5 
was stricter than Day 1 to ensure that only the most GFP positive cells were 
selected.
Figure 7.10. RNA Expression of shLMO4 PUER cells versus uninfected cells and 
MigRI infected cells.
Figure 7.11. Apoptosis assay at day 2 following infection using Annexin V (APC 
staining) and PI (PE channel). R4= Healthy cells, R2= cells committed to apoptosis, 
R3= apoptotic cells with a permeable membrane and R5 = dead cells/necrotic cells.
Figure 7.12. qPCR expression profile for LMO1 in Flk+ cells containing the Flag-
LMO1 construct before and after induction with doxycyclin.
Figure 7.13. Flow cytometry results showing the percentage of A2Lox cells 
differentiating to Tie2+ CD41+ during induction of Flag-LMO1 and shLMO1 (R4). On 
induction of LMO1 over-expression (Flag-LMO1) the percentage of cells drops from 
10.72% to 7.63% and on induction of the LMO1 knockdown (shLMO1) the 
percentage reduces from 10.51% to 4.84%.
Figure 7.14. qPCR expression profile for LMO4 in ES cells and in shLMO4 A2lox 
cells before and after induction with doxycyclin. shLMO1 Flk+ A2lox cells were also 
included as a control to check that shLMO1 did not influence LMO4 expression.
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INTRODUCTION
Although studies into the early stages of hematopoiesis have been carried out for 
many years, detail of the transcription factors and pathways involved is still lacking. 
During early embryonic development there are 2 clear types of hematopoiesis, 
primitive referring to the production of primitive or embryonic progenitor cells and 
definitive referring to the production of adult hematopoietic progenitor cells (Sturgeon, 
2013). The primitive progenitor cells produce primitive erythroblasts with both 
embryonic and adult hemoglobin along with macrophages and megakaryocytes and 
are unable to produce lymphoid cells and hematopoietic stem cells (Sturgeon, 2013 
& Lux, et al. 2008).  During definitive hematopoiesis the cells produced contain only 
adult hemoglobins and hematopoietic stem cells (HSCs) are also produced. HSCs 
are able to seed the liver, bone marrow and other organs to continue life long blood 
cell production (Sturgeon, 2013 & Lux, et al. 2008).
Primitive hematopoiesis occurs mainly within the yolk sac forming a belt of primitive 
blood cells around the embryo (Lux, et al. 2008). The process first starts with the 
differentiation of pluripotent stem cells (known as embryonic stem (ES) cells in in 
vitro systems). The  stem cells contained within blastocysts go though a number of 
stages of differentiation to form a colony, known as a hemangioblast, capable of 
differentiating into hematopoietic, endothelial and smooth muscle cells (Medvinsky, 
Rybtsov&Taoudi, 2011). The initial stages of differentiation were demonstrated by 
Fehling et al. 2003 showing that the cells go through a pre-mesoderm and a pre-
hemangioblast stage defined by differences in expression of cell surface markers (fig 
5.1). The main defining markers differing between the ES cell and hemangioblast is 
the expression of Flk-1 and Brachyury (Bry) (Fehling et al. 2003 & Gordon-
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Keylock&Medvinsky, 2011). The hemangioblast then goes on to form an intermediate 
endothelial stage known as hemogenic endothelium, which is defined by being Tie2hi, 
cKit+ and CD41- (Lancrin, et al. 2009). It has been shown that the transcription factor 
Scl (also known as TalI) is critical for the differentiation from the hemangioblast 
(Lancrin, et al. 2009 & Sturgeon, 2013). Once formed, the hemogenic endothelium is 
able to produce the primitive hematopoietic cells.
The primitive hematopoietic system has been demonstrated in vitro in a number of 
studies and is commonly used in the study of early hematopoietic cells (Lancrin, et al. 
2009). The early stages of differentiation in definitive hematopoiesis are less well 
understood and there is controversy around the in vitro system because there is 
currently no way to maintain the stem cells (Sturgeon, 2013). Hematopoietic stem 
cells (HSCs) are the key progenitor for definitive hematopoiesis and are found in the 
embryo from E10.5-11.5 (Sturgeon, 2013). In the same way as primitive 
hematopoiesis it is thought that a hemogenic endothelium is formed which is found in 
the yolk sack, dorsal aorta and placenta (Antas, et al. 2012). The definitive progenitor 
cells then bud from the surface of the endothelium where they can be sheared by 
blood flow and used to seed bone marrow and organs with HSCs (Antas, et al. 
2012). There are also some interesting studies looking at the effect of the shear force 
of blood flow on the chemical signals within the hemogenic endothelium and whether 
this may affect the type of cells produced (Antas, et al. 2012 & Wolfe &Ahsan 2013). 
There has been disagreement about the exact origins of HSCs however Boisset, et 
al. (2010) used time lapse confocal microscopy to image the production of HSCs in 
slices through the embryonic aorta of mice and showed budding off of HSCs which 
they defined as being Sca1+, C-Kit+, CD41+. The key difference which has been 
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identified in the formation of HSCs is the requirement for transcription factors Runx1 
and Sox17 which are not required in primitive hematopoiesis (Sturgeon, 2013 & 
Lancrin, et al. 2009).
The exact differences between primitive and definitive hemogenic endothelium are 
still to be identified as HSCs are yet to be produced in vitro. It is likely that increasing 
knowledge about the transcription factors involved in the process would be the key to 
progressing this. 
Figure 5.1 Early hematopoetic development showing some of the cellular markers 
and transcription factors involved (Fehling et al. 2003, Lancrin, et al. 2009, Sturgeon, 
2013 & Gordon-Keylock&Medvinsky, 2011).
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Relationship of the LMO Proteins to Early Stage Hematopoiesis
What relationship do the LMO family of proteins have to the early stages of 
hematopoiesis? The LMO (LIM Domain Only) family of proteins is of particular 
interest in relation to early hematopoiesis as they are thought to be involved in the 
regulation of transcription, through nucleating the formation of transcription factor 
complexes. This potentially gives them key importance in cell differentiation and cell 
fate (Matthews, et al. 2013). There is also evidence linking proteins within the family 
to development and diseases including some forms of T-ALL (T-cell Acute 
Lymphoblastic Leukemia), neuroblastoma and neural tube defects (Matthews, et al. 
2013 & Lee et al. 2005).
The LMO Protein Family
LIM Domains 
The family of LMO proteins are characterised by the presence of just two LIM 
domains and no other domains. Protein domains are individual units within a protein 
which are responsible for specific functions or interactions of the protein. A protein 
domain can be found across multiple proteins with different functions but with the 
structure of the domain remaining the same (EMBL-EBI, 2011).  A LIM domain is a 
protein-protein interaction site made up of two zinc finger domains and usually has a 
size of around 50-60 amino acids  (Zheng&Quanhui, 2007). The zinc finger domains 
are folded into the ʻtreble cleffʼ formation, are separated by 2 amino acids and contain 
8 conserved residues (Zheng&Quanhui, 2007). Zinc finger domains have been 
related to a diverse range of functions including DNA recognition, acting as 
transcription factors, regulating apoptosis and protein structure formation (Laity, et al. 
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2001).  Zinc fingers folded in the treble cleff formation are most commonly associated 
with binding directly to nucleic acids, however this has never been demonstrated for 
the LIM domain, which has only been shown to bind other proteins 
(Kadrmas&Beckerle, 2004).      
The LIM domain is named after the proteins in which it was first discovered Linl-1, 
Isl-1 and Mec-3 and has been shown to be present in proteins of all well studied 
eukaryotic organisms (Kadrmas&Beckerle, 2004). Proteins containing LIM domains 
have been found in both the cytoplasm and nucleus and can be linked to other types 
of domain or can be the only domain a protein has, for example in the case of the 
LMO proteins. Proteins with LIM domains can be broadly classified into four groups, 
nuclear only, LIM only, LIM actin associated and LIM catalytic, the LMO proteins are 
all members of the LIM only group (Kadrmas&Beckerle, 2004). As mentioned earlier 
the main function which has been demonstrated for the LIM domain is to bind to 
other proteins. Protein binding interfaces are crucial for the formation of complexes 
with other proteins which are required for many biological processes 
(Kadrmas&Beckerle, 2004). As a result of the large amount of variability within the 
non-conserved regions of the LIM domain different LIM domains are able to 
specialise, meaning that as a family LIM domains have a wide range of binding 
partners (Kadrmas&Beckerle, 2004). Although LIM domains do not bind DNA they 
have consistently been shown to be critical in regulating gene expression, often 
through transcriptional regulation. Even proteins with LIM domains located in the 
cytoplasm have been shown to move between the cytoplasm and the nucleus 
allowing involvement in transcription factor complexes (Zheng&Quanhui, 2007). 
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The LMO Family
There are 4 proteins within the LMO family, LMO1, LMO2, LMO3 and LMO4.All of 
these proteins have been shown to be implicated in development and in a range of 
human cancers (Wang et al. 2010). They all generally function within transcription 
factor complexes in the nucleus and are expressed in a large number of embryonic 
and adult tissues. Particularly high expression is seen in the nervous system 
especially during early development. The proteins share a fairly high level of 
similarity, with LMO1 and LMO3 sharing the highest similarity at 89% and LMO4 
being the least similar to others in particular LMO2 with a similarity of only 34% (Fig 
5.2) (Matthews, et al. 2013).
Figure 5.2. Similarities between the proteins in the LMO family (Modified from 
Matthews, et al. 2013).
LMO1
LMO1 has been shown to be mainly expressed within the nervous system however it 
has also been found in the thymus and kidneys of mice (Huret, 2013a). It was first 
discovered along with LMO2 when investigating chromosomal translocations 
resulting in a specific sub-type of T-ALL (Gill, 1995). LMO1 was identified near the 
break point of the t(11;14)(p15;q11) translocation in the T-ALL human cell line RPMI 
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8402 (Boehm, et al. 1988 & Matthews, et al. 2013). LMO 1 has also been implicated 
as an oncogene for neuroblastoma. Wang, et al. (2010) carried out a genome wide 
association study on neuroblastoma patients and identified four associated SNPs 
within the LMO1 gene. They also showed that over-expression of the LMO1 protein 
results in the increased proliferation of neuroblastoma cells and that knock-down of 
the protein using shRNA inhibited growth. 
An important role for LMO1 has also been shown in the homeostasis of gastric 
epithelial cells through regulation of apoptosis . Saeki, et al. (2007) showed that 
LMO1 has a regulatory effect on the GSDM gene which is known to be involved in 
apoptotic activity within pit cells and is often silenced in gastric cancer cells. LMO1 is 
not normally expressed within the hematopoeitc system and most of its functions 
appear to be shared with LMO2. As LMO2 is highly expressed and known to be 
critical for hematopoiesis, the great majority of research in this area is focused on 
LMO2. 
LMO2
The LMO2 protein is probably the most researched of all the proteins within the LMO 
family due to its significant involvement in hematopoiesis. It is important during 
embryonic development as it is required for the production of primitive 
erthythreocytes and haemogenic endothelium which leads to HSCs and the definitive 
hematopoietic system (Huret, 2013b). LMO2 is also important for the early 
hematopoietic progenitors and the differentiation from HSCs to committed blood cells 
including the erythrocyte lineage in both embryos and adults. 
A study of LMO2 knock-out mice showed that LMO2 is needed for erythropoiesis 
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within the yolk sack and knock-out mice died at E9-10 (Warren, et al. 1994). In 1997 
Wadman, et al. showed that LMO2 formed a transcription factor complex with 
GATA-1, TAL1 (Scl) and Ldb1 in erythroid cells and that this complex was able to 
bind DNA, thereby regulating transcription. It has since been confirmed in other 
studies that this transcription factor complex is essential for erythropoiesis which is 
why knock-out mice did not survive past the embryonic stage (Kerenyi & Orkin 2010). 
In addition to the involvement of LMO2 in erythropoiesis, LMO2 has a very significant 
involvement in T-ALL in a similar way to LMO1. Translocations resulting in LMO2 
overexpression include t(11;14)(p13;q11) and t(7;11)(q35;p13) which fuse genes 
highly expressed in T-cells upstream of the LMO2 gene resulting in its 
overexpression (Matthews, et al. 2013). Along with its involvement in T-ALL LMO2 
has also been implicated in B cell lymphomas. LMO2 is expressed in both normal B 
cells and B-ALL cells, it has been shown that an increased level of expression in B-
ALL cells is correlated with better clinical outcomes (Malumbres, et al. 2011). 
Involvement in a large transcriptional binding complex has been shown in these cells 
which interestingly differs from complexes seen in erthyropoiesis and T-cell 
development due to the absence of GATA1-3. Overexpression of LMO2 however is 
not a sign of better clinical outcome in all types of B-cell lymphoma. It has been 
shown in ~1% of DLBCL (Diffuse Large B Cell Lymphoma) cases a translocation 
takes place which results in the expression of an extra transcription factor leading to 
LMO2 upregulation (Matthews, et al. 2013). The presence of LMO2 in this case is a 
sign of poor clinical outcome and it has been shown that LMO2 promotes 
proliferation of these cells. This shows that the background of other transcription 
factors within the cell also has a significant impact on the action of LMO2 reinforcing 
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the fact that due to its role in protein-protein interaction the actual outcome of 
inappropriate regulation of LMO2 can vary greatly. 
LMO2 has also been implicated in solid tumors, including prostate cancer. LMO2 has 
been shown to be upregulated in the later stages of prostate cancer and in 
experiments of forced overexpression it has been shown to increase the invasive 
abilities and spread of cancer cells (Ma, et al. 2007). It is suggested that this results 
from the disruption of normal transcription factor complexes causing the repression of 
E-cadherin, a protein important in cell adhesion, which restricts the spread of 
cancerous cells (Matthews, et al. 2013). There is no evidence to suggest that 
overexpression of LMO2 alone can induce prostate cancer, however, it is clear that in 
a lot of cancers a number of mutations and deregulations can build up over time to 
progress the tumor growth.
LMO1 and LMO2 in T-ALL
LMO1 and LMO2 share a relatively high level of similarity, as do all proteins in the 
LMO family and as mentioned previously both LMO1 and LMO2 have been 
implicated in T-ALL. In ~50% of cases either LMO1 or LMO2 is upregulated and 
LMO2 upregulation occurs in ~9% of pediatric cases as a result of chromosomal 
translocations or a cryptic deletion (Matthews, et al. 2013). The reason for the 
upregulation is thought to be as a result of translocation of genes which are highly 
expressed in T-cells near to the LMO1 or LMO2 gene resulting in increased 
expression (Matthews, et al. 2013). In the case of the cryptic deletion Vlierberghe, et 
al. 2006 showed that this occurs in a negative regulatory region upstream of the 
LMO2 gene inactivating the regulatory effects of this region on LMO2 expression. 
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The development of T-ALL as a result of LMO2 upregulation was confirmed as a 
result of a side effect of gene therapy trials for x-linked SCID (Severe Combined 
Immunodeficiency Disorder). In the gene therapy the IL2RG gene was inserted using 
a retroviral vector to replace the mutated version causing the condition. Although the 
gene therapy was relatively successful in increasing the number of T-cells, after 
several years some of the patients developed T-ALL. This was caused by the 
insertion of the IL2RG gene upstream of the LMO2 gene resulting in overexpression 
of LMO2 and the eventual development of T-ALL (Hacein-Bey-Abina, et al. 2008 & 
Hacein-Bey-Abina, et al. 2003). 
The upregulation seen in T-ALL without translocations is thought to result from the 
activation of a feedback loop which promotes expression of LMO2. The LMO2 
protein has been shown to form a complex with ETS transcription factors which can 
then bind to the LMO2 promotor and upregulate expression (Matthews, et al. 2013 
&Oram, et al. 2010). This means that a small increase in the expression of LMO2 or 
other related transcription factors may be able to unbalance the homeostasis of the 
system and form a large excess of LMO2. This is important because in the normal T-
cell differentiation pathway LMO2 is downregulated throughout the process to a point 
where it is undetectable in the mature cells (Matthews, et al. 2013). McCormack, et 
al. (2010) demonstrated that forcing expression of LMO2 at the DN3 stage of the 
pathway resulted in self-renewal of these cells, effectively giving them a property of 
stem cells, which appears to be a first step in the progression to leukemia. Although 
this is a clear route implicating LMO2 in disrupting normal functioning in the thymus, 
T-ALL takes a significant period of time to develop after this extra proliferation of 
cells, between 2 and 6 years in humans (Hacein-Bey-Abina, et al. 2008). It is thought 
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that this is because the self renewal of cells at the DN3 stage is not directly 
responsible for leukemia as these cells are still able to develop into functional T-cells 
(McCormack, et al. 2010). It has been suggested that the pool of extra cells formed 
at this stage increases the likelihood of mutagenesis, inactivating tumor suppressors 
such as Cdkn2a and disruption of the NOTCH pathway resulting in the final high 
proliferation with low differentiation seen in T-ALL (Matthews, et al. 2013). This pool 
of cells represents ʻleukemic stem cellʼ like cells which are a separate population to 
the leukemic cells. McCormack, et al. 2010 showed, in mice, that this pool of cells in 
very hard to target therapeutically resulting in a high percentage of relapse. This may 
partially be because the cells exhibit senescence whereas most cancer therapies 
target rapidly dividing cells.
LMO3
LMO3 is the least researched of the LMO family, however, as with the other members 
of the family it has been implicated in development and in cancer. Isogai, et al. 2011 
showed that LMO3 and HEN2 (a neuronal transcription factor) are significantly up-
regulated in unfavorable neuroblastoma tumors and that cells which over-expressed 
LMO3 had an increased growth rate and rapidly developed into tumors in mice. 
Further studies have shown that LMO3 and HEN2 in complex reduces the ability of 
another transcription factor HES1 to negatively regulate Mash1 (a proneuronal 
protein) which is known to be critical for neuronal development and is highly 
expressed in neuroblastoma cells (Isogai, et al. 2011). Studies have also suggested 
that LMO3 may form complexes with CIB (a calcium and integrin binding protein) 
which results in LMO3 activity moving from the nucleus to the cytoplasm and possibly 
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inhibiting cell proliferation (Hui, et al. 2009).
LMO1 and LMO3 exhibit the highest similarity within the LMO family and have been 
shown to be able to compensate for each other. Tse, et al. (2004) demonstrated that 
when knocking-down LMO1 and LMO3 separately, in mice, no discernible phenotype 
could be found. Although LMO1 is much more highly expressed during neural 
development than LMO3 the knockdown of LMO1 had no apparent neural defects. 
When both proteins were simultaneously knocked down this resulted in death shortly 
after birth. No morphological defects were found.However, it was hypothesised that 
death probably resulted from neural defects due to the lack of expression of LMO1 
and LMO3, which would usually be found within the developing neural system. The 
compensatory effect of these two members of the LMO family raises potentially 
interesting questions regarding the extent to which other members of the family may 
compensate and this may be important to remember in studies such as this, involving 
the knockdown of just one member of the family.
LMO4
LMO4 has the least similarity to the other members of the LMO family and was first 
discovered in the cDNA library for a human breast tumor (Racevskis, et al. 1999). 
The majority of research around LMO4 is linked to its role in breast cancer, however, 
it has also been shown to be implicated in squamous cell carcinoma of the oral 
cavity, neural tube development and a survival advantage in pancreatic cancer 
(Matthews, et al. 2013 &Tse, et al. 2004). Unlike other members of the LMO family, 
LMO4 has been shown to be widely expressed across tissues in both embryonic and 
adult mice with highest expression in proliferating epithelial tissue (Sum, et al. 
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2005a). LMO4 is essential in the early stages of development. Knockout mice have 
shown embryonic lethality due to failed neural tube closure resulting in exencephaly 
and anencephaly (Tse, et al. 2004). Kwong, et al. 2011 showed an upregulation of 
LMO4 and Ldb1 in the nuclei of squamous cell carcinoma cells, particularly at the 
ʻinvasive frontʼ, supporting a significant role in cancer progression. 
LMO4 was first identified in breast cancer as an auto-antigen (a protein generated by 
the tumor which evokes an immune response).It is associated with a poor prognosis 
(Matthews, et al. 2013) and in murine systems it was shown that over expression of 
LMO4 can result in tumor induction within mammary glands. This is also supported 
by siRNA knock-down of LMO4 in human cancer cell lines which shows a reduction 
in cell proliferation (Sum, et al. 2005b).The exact route by which LMO4 results in 
tumor induction is largely unknown, however, a number of potential routes have been 
identified in different cancer sub-types. 
Unlike LMO1 and LMO2 there is no evidence to suggest that LMO4 induces stem cell 
like self renewal properties in cells (Matthews, et al. 2013). A major route by which 
changes in LMO4 expression act is via the cell cycle. Montañez‐Wiscovich, et al. 
(2010) showed that knock-down of LMO4 in all examined sub-types of breast cancer 
resulted in G2/M arrest in the cell cycle. They also showed that other effects included 
increased cell death, amplification of centromeres and faults in spindle formation. 
Similar phenotypes also occur when LMO4 is over-expressed suggesting that for 
normal functioning a highly controlled level of LMO4 is required. 
Studies have shown that LMO4 has a significant role in transcriptional regulation in 
breast cancer and a number of different interactions and binding partners have been 
identified. One of the most significant of these interactions is probably with the 
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BRCA1 protein which is known to be an active tumor suppressor in both breast and 
ovarian cancers. Sum, et al. (2002) showed that LMO4 is able to form a complex with 
CtIP and BRCA1, repressing the transcriptional activation of BRCA1 and therefore 
promoting cancerous cell growth in breast tissue. LMO4 has been shown to interact 
with repressor proteins such as MTA1 and RBBP8 which can act to repress ERα a 
common phenotype in the development of breast cancer(Singh, et al. 2005, 
Zheng&Quanhui, 2007 & Matthews, et al. 2013). It has also been shown that through 
this same pathway LMO4 can activate transcription by preventing binding of HDAC2 
to chromatin and possibly also through the recruitment of GATA6 (Wang, et al. 2007 
&Setogawa, et al. 2006). LMO4 has also been suggested to interact with the 
transcription factor DEAF1, where LMO4 may be responsible for localisation of 
DEAF1 in the nucleus (Matthews, et al. 2013). 
The final way in which LMO4 overexpression may promote cancerous cell 
proliferation is through enhancing the TGFβ growth factor. It is known that TGFβ is 
involved in mesenchymal-epithelial interaction in cancer and development so its 
interaction with LMO4 is another potential pathway for the induction of tumor growth 
(Lu, et al. 2006).
Although most research looks at the negative clinical outcome of LMO4 
overexpression there is also evidence to suggest that its overexpression can result in 
a positive outcome. In patients with pancreatic cancer it has been shown that tumors 
expressing higher levels of LMO4 give an improved outcome when surgically 
removed than those which do not (Murphy, et al.2008 & Yu, et al. 2008). It is unclear 
why this is and again potentially shows a role of LMO4 in cancer development and 
also identifies it as an important biomarker. 
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It is clear that none of the LMO family of proteins is able to function alone in disease 
or normal conditions. All proteins within the family are essential mediators in the 
formation of transcription factor complexes and through this route their deregulation 
has a key influence on both leukemias and solid tumors. Understanding the function 
of these proteins is therefore very important as this will increase our knowledge of 
tumor biology in general and more particularly they may prove to be therapeutic 
targets.
The LMO Family as Therapeutic Targets
Due to the oncogenic properties of LMO2 efforts have been made to develop ways of 
targeting and repressing LMO2 expression. Currently two methods for LMO2 
targeting have been demonstrated, the first involves the introduction of an intrabody, 
an intracellular antibody which is able to bind to LMO2. This was shown to disrupt 
LMO2 function in T-ALL cells making it the basis for a potential therapeutic agent 
(Nam, et al. 2008). The second method involves the introduction of a peptide 
aptamer which binds to the second LIM domain of LMO2 and has again been shown 
to successfully disrupt the activity of LMO2 within T-ALL cells (Appert, et al. 2009). 
Both of these methods have been shown to halt tumor cell growth in T-ALL which not 
only confirms the role of LMO2 in T-ALL but also increases the possibility of drug 
development. Similar targeting strategies have been suggested for LMO4 in breast 
cancer, however, as the LMO proteins all have essential roles in normal cellular 
function as well as cancer general disruption of these proteins is not therapeutically 
viable (Matthews, et al. 2013). Methods would be required to make these inhibitors 
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specifically target cancerous cells and use of other therapeutics to form a 
combination therapy would be necessary.
Aims and Objectives
The aim of this study is to look for functions of LMO1 and LMO4 within 
hematopoiesis, particularly at the early stages. This is attempted through the 
development of shRNA knockdowns and overexpression constructs for the two 
proteins in PUER cells which are early myeloid progenitor cells in mice and A2lox, a 
doxycyclin inducible mouse embryonic stem cell system.
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MATERIALS AND METHODS
The overall experimental method was to clone overexpression and shRNA 
sequences into PUER cells and A2lox ES cells to achieve knockdown of the LMO1 
and LMO4 proteins. This was then followed up by studies of the phenotype of the 
cells to assess whether knockdown had been successful and whether the knockdown 
had any significant effect on the cell function or phenotype.
Cell Lines
All cell lines were cultured in humidified incubators at 37°C with 2% CO2 using 
Corning tissue culture flasks. Plat-E cells were cultured in DMEM (Dulbecco's 
Modified Eagle's Medium) with 10% FCS, Penicillin/Streptomycin and Glutamax. 
Cells were split regularly before full confluence to ensure that the cell line remained 
healthy. PUER cells were cultured in IMDM with 10% FCS, Pen/Strep, Glutamax and 
5ng/ml recombinant mouse IL-3 and were split when cells reached >1million per ml. 
When necessary ,e.g. after thawing out cells from liquid nitrogen, excess debris was 
removed from the cells by differential density centrifugation using Lympholyte-M and 
centrifuging at 1,000g for 20 minutes with reduced deceleration. The suspension of 
healthy cells was then removed and washed in PBS before returning to growth 
medium. 
A2Lox ES cells were cultured based on Fehling, et al. (2003) in DMEM with 
recombinant mouse LIF on a layer of inactivated MEF (Mouse embryonic fibroblast) 
cells until differentiation was required.
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Media composition for ES Cell Culture
FCS (15%)" " " " " " 75.0 ml
100x Pen/Strep " " " " " 5.0ml
100x L-glu" " " " " " " 5.0ml
Recombinant Mouse LIF" " " " 5.0ml
MTG (0.15mM) " " " " " 0.5ml
Hepes Buffer 1 M stock" " " " 12.5ml
Invitrogen KO DMEM" " " " to 500ml
 Two days prior to differentiation the cells were transferred to gelatinized plates in the 
same media to allow them to adjust to the new type of plate and then one day before, 
transferred into IMDM still containing recombinant LIF. At day zero the cells were 
transferred to low adherence plates with differentiation medium so that they could 
grow into embryonic bodies. The cells were then cultured for between 3.2 and 3.75 
days to allow development of hemangioblasts. At this point Flk1+ cells were 
separated by MACS separation and were then returned to culture for four days in 
blast medium which includes VEGF allowing the development of CD41+ 
haematopoietic precursor cells. 
Production of shRNA sequences
The shRNA sequences were designed using RNAi Central shRNA designer from 
Hannon Lab based on LMO1 and LMO4 sequences sourced from NCBI BLAST. The 
sequences were also tested against NCBI BLAST to ensure that they were only 
found in the desired protein and any which were present in other proteins were 
discounted. Based on these generated sequences the oligonucleotides were ordered 
from Sigma-Aldrich. Initially three oligonucleotide sequences were designed for each 
protein however this was later increased to seven for LMO1 (Table 6.1)
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Table 6.1 Oligonucleotide sequences for LMO1 and LMO4 shRNAʼs designed using 
RNAi Central shRNA designer from Hannon Lab
Name Sequence (5ʼ to 3ʼ)
shLMO1 #1 TGCTGTTGACAGTGAGCGAATGCTCTCCGTCCAACCTAAGTAG
TGAAGCCACAGATGTACTTAGGTTGGACGGAGAGCATCTGCCT ACTGCCTCGGA
shLMO1 #2 TGCTGTTGACAGTGAGCGATGTGACTGTCGCCTGGGCGAGTAG 
TGAAGCCACAGATGTACTCGCCCAGGCGACAGTCACAGTGCCT ACTGCCTCGGA
















Cloning of LMO1 and LMO4 shRNAs into the pMSCV cloning vector
The shRNA sequences were first cloned into the pMSCV cloning vector which is a 
modified version of the MigRI vector based on the protocol by Stegmeier, et al. 
(2005) and includes a gene for hygromycin and ampicillin resistance. The MigRI 
vector has an IRES GFP between two viral LTRs and can be used to clone a gene in 
front of the IRES GFP and then using Plat E cells produce viral particles. The pMSCV 
vector has the IRES GFP sequence in MigRI replaced with the miR-30 sequence. 
This then means that the hairpin in the miR-30 sequence can be replaced with a 
designed shRNA sequence to silence a gene of interest.
To begin the cloning process the oligos first had restriction sites added by carrying 
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out a PCR using pSM2C primers which add the XhoI and EcoRI restriction sites 
(Table 6.2). An optimised PCR reaction was developed for the shLMO1 cloning to 
ensure that maximum efficiency was achieved (Fig 6.1). A column based PCR clean 
up was performed on the products using the ʻNuceloSpinʼ PCR clean up kit protocol. 
The cleaned up samples were digested using EcoRI and XhoI restriction enzymes 
and then separated by gel electrophoresis on a 3% agarose gel. The pPrime plasmid 
was also digested using EcoRI and XhoI and separated on a 1% agarose gel. The 
size of the bands produced was confirmed against the ladder and they were cut from 
the gel. The DNA was eluted from the gel using the ʻNuceloSpinʼ gel extraction 
protocol and DNA concentration was measured using a NanoDrop. The shRNA insert 
was ligated into the pPrime backbone using 0.5μl quick T4 DNA Ligase, 2μl 5x buffer, 
100ng pPrime Backbone and 12.5ng of insert, the reaction was then made up to 10μl 
with water. The ligation was incubated at room temperature for 1 hour prior to use for 
transformation of competent E.coli. Unless otherwise stated all digestions were 
carried out using ThermoScientifc Fast Digest enzymes and Fast Digest Buffer at 
37°C for 30 minutes.
Figure 6.1 Optimised PCR program for cloning of shLMO1 sequences.
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Table 6.2 Primer sequences for pSM2C - Restriction sites highlighted in bold.
Primer Sequence (5ʼ to 3ʼ)
pSM2C Fwd - (XhoI 
restriction site)
GATGGCTGC/TCGAGAAGGTATATTGCTGTTGACAGTGAGCG
pSM2C Rev- (EcoRI 
restriction site)
GTCTAGAGG/AATTCCGAGGCAGTAGGCA
Transformation of Competent E.coli
Transformation of chemically competent E.coli (Bioline CH3-Blue) was carried out 
based on the Bioline protocol. In short, 2.5μl of the ligation was added to 25μl of 
competent cells, which after a short incubation on ice underwent heat-shock at 42°C 
for 30 seconds before returning to ice. LB medium was then added and the samples 
were incubated at 37°C for 1 hour. Finally the cells were spread onto LB plates 
containing 100μg/ml Ampicillin and allowed to grow at 37°C overnight. Colonies from 
these transformations were picked and cultured for mini-preps based on the protocol 
by Zhou, Yang & Jong, 1990. A sample of the DNA produced from the mini-preps was 
then digested with MfeI and XhoI to check for the correct insert size. MfeI was used 
instead of EcoRI as this produces a slightly larger fragment size which is easier to 
identify when separated by gel electrophoresis. Once separated on an agarose gel 
each mini-prep sample was checked for the correct band size to show that the insert 
was present. For all those where the insert was present a sample was sent for 
sequencing using the MSCV Fwd primer, which helped to ensure that the shRNA 
insert sequence was correct before transfecting it into cells or further subcloning. 
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Transfection of Plat-E cells
To successfully clone the shRNA sequences into PUER cells it was first necessary to 
transfect it into Platinum-E (Plat-E) retroviral packaging cells. Maxi-preps were 
carried out to produce larger quantities of the plasmids with the correct insert. To 
carry out the transfection Plat-E cells were cultured to between 70% and 80% 
confluent and transferred to fresh medium several hours prior to transfection. The 
transfections were carried out using Mirus TransIT transfection reagent following the 
Mirus protocol. For 15cm (176cm2) dishes this involved mixing 21ng of the plasmid 
DNA with 2.1ml of serum free medium and adding 63μl MirusTransIT. This was then 
incubated at room temperature for 15 - 30 minutes before adding it drop-wise to the 
Plat-E cells. The cells were then returned to incubate at 37°C overnight. After 
overnight incubation the cultures were then moved to a 30°C incubator for 3 days, 
allowing the viral particles produced by the cells to reinfect the cells significantly 
increasing the viral particle yield. 
Infection of PUER cells
Using the viral particles produced by the Plat-E cells, PUER cells were infected to 
insert the shRNA sequences. PUER cells were infected by spin infection on 6-well 
plates.  Between 0.5x106 and 0.75x106 cells per well were suspended in the 
supernatant from the Plat-E cells and centrifuged for 2 hours at 2,200 RPM. Once 
centrifuged, the plates were returned to a 37°C incubator to allow recovery for 1 hour 
before washing in IMDM medium and returning in their own culture medium at 37°C. 
Following this, after 24 hours hygromycin selection was started by addition of 10μl 
50mg/ml hygromycin per 1ml of media. Cells were then checked daily against a 
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control to look for cell death and outgrowth of targeted cells.
Re-cloning
- pPrime/MSCV GFP
Due to a possible apoptotic phenotype of shLMO4 in PUER cells one of the shRNA 
sequences was re-cloned into an MSCV plasmid which contained GFP rather than 
hygromycin resistance. This allowed for targeted cells to be monitored more rapidly, 
both visually and by flow-cytometry. The original shLMO4 pPrime plasmid was 
digested with BglII and MfeI and MSCV GFP was also digested as a new backbone. 
The fragments were separated on agarose gel and the DNA extracted from the gel 
for ligation. The ligation, transfection, transformation and infection protocols were 
repeated as before, with the omission of the hygromycin selection.
- p2lox
To achieve insertion of the sequence into the ES cell A2lox inducible system it was 
necessary to re-clone the insert, together with the surrounding miR-30 sequence into 
the p2lox plasmid. By initially using the MigRI plasmid IRES GFP gets inserted 
behind the cDNA before the re-cloning into p2lox. The digestions with EcoRV and 
EcoRI for this re-cloning were performed sequentially, because of the presence of an 
extra EcoRI restriction site immediately next to the EcoRV  site. Firstly p2lox was 
digested with EcoRV for 1 hour, after which EcoRI was added and the digest was 
allowed to continue for a further hour to ensure the plasmid was fully digested. The 
pPrime plasmid containing the shLMO insert was first digested with BglII for 1 hour 
and then cleaned using the ʻNucleoSpinʼ PCR column clean up protocol. Following 
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this large fragment DNA polymerase I enzyme was used along with dNTPs to create 
blunt ends compatible with the EcoRV site, a further PCR cleanup step was carried 
out prior to digestion with MfeI. The products of these digestions were again 
separated by gel electrophoresis and the eluted DNA ligated to make the final 
plasmid. 
Transfection of p2lox into A2lox ES cells
The A2lox cells were transfected with the p2lox plasmids via electroporation. After 
washing with PBS 1.2x106 cells were mixed with 150μl of PBS, 20μg of the sh p2lox 
plasmid and 20μg of Cre-expressing plasmid. This was then elctroporated for 7 
milliseconds at 240volts before being returned to growth medium. Following 
electroporation the cells contain both the p2lox plasmid including the sh construct 
and IRES GFP and a general CRE expressing plasmid. CRE-mediated 
recombination then places the cDNA and IRES GFP behind a dox-inducible 
promoter, which is already in the A2ox cells. A PFK promoter also contained within 
the plasmid is inserted in front of the Neomycin resistance gene which is already 
present in the cell meaning that neomycin resistance would be present in 
successfully transfected cells. After 7 days of selection individual colonies were 
picked of which 6 were frozen and 1 was used for initial tests.
Testing the constructs
Once produced it was necessary to test the constructs to ensure that the shRNAs 
had the desired effect of knocking down the proteins. This was first tested at the Plat-
E transfection stage, Plat-E cells were transfected with both an shRNA and an over-
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expressing construct for the protein containing GFP. This technique made it possible 
to compare fluoresence using fluorescence microscopy to see if the over-expressing 
construct was knocked down by the shRNA construct. The shLMO1 constructs were 
also tested in PUER cells by infecting PUER cells which already had an over 
expression construct for LMO1 with the sh construct. Fluoresence of these cells 
could then be analysed via Flow cytometry to identify the functional constructs. Flow 
cytometry was also used to analyse the shLMO4 GFP PUER cells to assess the 
infection efficiency and to monitor their survival rates. 
Apoptosis Assay
An apoptosis assay was used on the shLMO4 GFP and the MigRI PUER cells to look 
for an apoptotic effect of the protein knock down. The assay used Annexin V and PI 
(Propidium Iodide) staining to identify apoptotic cells by flow cytometry. This was 
carried out using the eBioscience (2010) protocol which involves washing a sample 
of cells firstly in PBS and then in Annexin V binding buffer. Annexin V antibody is then 
added at 5μl per 100μl and incubated at room temperature for 15 minutes. After 
incubation the cells underwent a further wash in Annexin V buffer before being 
resuspended in 350μl and having 10μl of PI added immediately prior to analysis. The 
cells were analysed by flow cytometry detecting APC for the Annexin V, PE for the PI 
staining and FITC to detect GFP to be able to identify the successfully infected cells. 
Western Blotting
Western blotting was used to determine the protein levels in both normal and 
transfected cells to assess the effect of the construct. Protein extract from both Plat-E 
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and PUER cells was produced by suspending the cells in loading buffer and boiling 
at 95°C for 5 minutes to  denature proteins. SDS gels were loaded with up to 20μl of 
sample and run at 75V until the samples were in the running gel and then 150v until 
the smallest band of the ladder reached the end of the gel. Gels were blotted onto 
nitrocelulose membranes using an Invitrogen iBlot.Prior to the addition of antibodies 
ponceau-s stain was used to check for the presence of protein and equal loading on 
the membranes. Membranes were blocked using an appropriate blocking agent 
depending on the antibody (5% Milk in PBS-T or 5% Horse Serum in PBS-T). The 
secondary antibodies used were LiCor 800 antibodies which allowed imaging of the 
membranes on a LiCor infrared scanner. 
qPCR
To carry out QuantitativePCR (qPCR), RNA extractions were performed on a range of 
cells. All RNA extracts were carried out using the QiagenRNeasy Mini Kit and final 
samples were eluted in 30μl of buffer. From these cDNA was produced using 1μl 
BiolineTetro Reverse Transcriptase, 1μl oligo(dT), 0.5μl 25mM dNTPs, 4μl Reverse 
Transcriptase Buffer, 1μl RNAseOut (RNase inhibitor), 10μl water and 2.5μl (1μg) 
RNA. This was then incubated at 45°C for 30 minute and 85°C for 5 minutes before 
storage at -20°C.
QuantitativePCR was then carried out using this cDNA to assess the expression of 
LMO1, LMO2 and LMO4 proteins in the cells used within the study. It was also used 
to assess the efficiency of the knockdown of LMO1 and LMO4 by the shRNA 
constructs. qPCR was carried out in 96-well plates with 5μl SybrGreen PCR master 
mix, 0.25μl (10 uM each) primers, 2.5μl cDNA and 2.25μl of water in each well. A 
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standard curve was produced for each set of primers using serial dilutions of the 
cDNA. Primers for the GAPDH gene were used for normalisation. The plates were 
run using an ABI 7500 Real-Time PCR System with a standard program and melting 
curve (Fig 2.2). Calculations were carried out to normalise the expression against 
GAPDH and then plots of the expression levels were produced.
Figure 6.2. qPCR Program for RNA expression analysis.
Immuno-staining and Confocal Microscopy
To confirm the location of the LMO proteins within the cells immuno-staining and 
confocal microscopy of PUER and Flk+ ES cells cells was carried out. Cells were 
spun down at 300g before being washed in PBS with 2% FCS, 2% PFA and 0.05% 
tween. This was left to incubate for 5 minutes at room temperature and then washed 
twice with PBS+ 2% FCS + 0.05% tween. After washing the cells were resuspended 
in 100μl of the PBS solution and each sample had 1μg of primary antibody for one of 
the LMO proteins added. This was incubated at 4°C for 30 minutes before a further 
three washes and the addition of 1μg of secondary antibody. After a further 
incubation period three more washes were carried out and then the cells were 
transferred to slides using a cytospin. The final slides had Gold anti-fade regent with 
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DAPI applied to prevent the antibodies fluorescence from fading and also to stain the 
DNA within the cell. The slides were then analysed using an Zeiss LSM 510 confocal 
microscope.
Flow Cytometry and FACS
Flow cytometry was used to check the functioning of the LMO1 and LMO4 
knockdown constructs in Plat E, PUER and Induced A2Lox ES cells. Plat E cells 
were prepared by first washing with PBS and then trypsinising prior to resuspension 
in PBS containing 10% FCS. PUER and A2Lox cells were prepared in a similar way 
but without the use of trypsin. The prepared cells were then run on a Cyan Flow 
Cytometer and the results analysed using  Summit 4.3. FACS ( Florescence Assisted 
Cell Sorting) was used to select cells containing the LMO4 knockdown construct for 
further analysis. Cells were prepared in a similar way to the flow cytometry analysis 
and returned to their standard growth media. 
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RESULTS
Expression of LMO Proteins
The expression of LMO1, LMO2 and LMO4 were demonstrated by qPCR within cells 
related to the early stages of hematopoiesis. Prior evidence suggested that LMO1 
was only expressed in Flk+ cells so to confirm this two ES cell lines (CCB and A2Lox) 
with independent backgrounds were used. The results showed only very low levels of 
LMO1 expression in both ES cell lines and a clear upregulation in Flk+ cells. The 
expression levels in these cells prior to the Flk+ stage are very low and the 
expression within the myeloid progenitor PUER cells is also very low suggesting 
LMO1 is mainly needed at the intermediate Flk+ stage of the differentiation process. 
The levels of LMO2 are very low within the undifferentiated ES cells (CCB and A2lox) 
similar to LMO1. A higher level of expression is present in both the Flk+ cells and 
PUER cells. It is notable that the level in PUER cells is comparably higher than 
LMO1 and drops when the PUER cells undergo further differentiation.  LMO4 is 
expressed at a low level in the undifferentiated ES cells (CCB and A2lox) and 
increases to a somewhat higher level in Flk+ haemangioblast cells, which was similar 
to the level observed in both undifferentiated and differentiated PUER cells (fig 7.1). 
Western blots using LMO1, LMO2 and LMO4 antibodies were also carried out across 
these cell types, however, the presence of the proteins could only be distinguished in 
over expressing cells for each protein. As it had been previously suggested that the 
LMO proteins were mainly located within the nucleus confocal microscopy was 
carried out on cells stained for DAPI and each of the LMO proteins. Along with this 
further western blots were also carried out using nuclear extract from A2Lox cells and 
A2Lox Flk+ cells. These results showed that only LMO2 was present in nuclear 
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extract from Flk+ cells and this localisation of LMO2 to the nucleus can also been 
seen in the confocal microscopy images. A low level of LMO4 was also shown in the 
ES cell nuclear extract but not in the Flk+ cells. From these westerns it was not 
possible to determine if this was also the case for LMO1 as the antibody bound 
unspecifically to degraded proteins in the ES nuclear extract sample (FIG 7.2).
Figure	  7.1.	  qPCR	  results	  comparing	  expression	  levels	  of	  LMO1,	  LMO2	  and	  LMO4	  to	  
GAPDH	  on	  cDNA	  from	  cells	  at	  varying	  differentiation	  stages	  from	  the	  earliest	  stage	  ES	  
cells	  (CCB	  and	  A2Lox)	  to	  Flk+	  Hemangioblast	  type	  cells	  and	  Oinally	  myeloid	  progenitor	  
cells	  (PUER)	  and	  differentiated	  progenitors.
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Figure 7.2. Western blots using αLMO1, αLMO2 and αLMO1 antibodies on A2Lox 
ES cell nuclear extract (ES NE) and Flk+ cell nuclear extract (Flk+ NE). Flag LMO1 
and Flag LMO4 in PUER cells were also used as positive controls for LMO1 and 
LMO4. Confocal microscopy images show Flk+ ES cells stained for LMO1, LMO2 or 
LMO4 (Green) and DNA/DAPI showing the nucleus (RED). This shows LMO1 to be 
mainly cytoplasmic, LMO2 to be mostly nuclear and LMO4 to be both in Flk+ ES 
Cells.
Cloning shLMO1 and shLMO4 - pMSCV (pPrime)
The first stage of the cloning process required the addition of restriction sites to the 
shRNA oligonucleotides using PCR. All six initial reactions (3 x shLMO1 and 3 x 
shLMO4) showed a product of expected size (Fig 7.3). The products were then 
digested with EcoRI and XhoI for insertion into the pMSCV vector, this produced 
fragments of ~120bp which could then be eluted from the gel for use in the ligation 
reaction.
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Figure 7.3. Agarose gel image showing PCR products from shLMO1 and shLMO4 
reactions with pSM2C primers.
Following ligation and transformation into competent E.coli the DNA was extracted 
and digested with BglII and MfeI enzymes to check for the successful insertion of the 
insert into the plasmid and its amplification within the E.coli. Most samples for both 
shLMO1 and shLMO4 showed a band at ~350bp which was compared to a positive 
control (FIg 7.4). DNA from some of these samples was sequenced and showed at 
least one correct sequence for each of the 6 shRNAs with the exception of shLMO1 
#2 which did not show a complete sequence due to a problem in the sequencing 
reaction. This was probably caused by a high GC-rich internal complementarity within 
the designed part of the shRNA sequence, which can prevent proper denaturation 
during the sequencing reaction.
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Figure 7.4. Digestions with BglII and MfeI of ligated shLMO1 and shLMO4 inserts 
after mini-preps. +ctrl shows the expected vector and insert sizes of positive clones, 
all clones showing an insert band of this size were regarded as positive.
After the functional validation of the shRNA constructs (descirbed below) we 
designed a further four constructs for shLMO1. Initially a number of failed attempts to 
produce a successfully ligated plasmid for these occurred, so optimisation of the 
initial PCR reaction was carried out. By creating a two stage PCR program with an 
initial 6 cycles with a 60°C annealing temperature and then a further 36 cycles with 
the annealing temperature increased to 68°C. This resulted in much cleaner bands 
which could be easily extracted from the gel with less chance of other fragments 
being included (fig 7.5). 
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Figure 7.5. PCR optimistation for cloning of the shLMO1 constructs. Products after 
digestion with EcoRI and XhoI.
Functional Validation of shRNA Constructs
To test the shRNAs a co-transfection of Plat-E cells was carried out with each of the 
shLMO1 and shLMO4 constructs and plasmids for the over expression of the LMO1 
and LMO4 proteins with IRES GFP.  These cells were analysed visually by 
fluorescence microscopy and by flow cytometry which showed that constructs #2 and 
#3 for LMO4 were functioning correctly and knocking down the over expressed 
protein and that none of the shLMO1 constructs were working effectively. Based on 
these results shLMO4 #2 was used for further study (Fig 7.9) and the further four 
shLMO1 constructs were designed. 
Once the extra shLMO1 constructs were successfully produced and sequenced 
these were transacted into Plat-E cells using the same co-transfection technique as 
previously described. The resulting cells showed a more significant reduction in GFP 
level of construct #6 than the control and other constructs when compared visually by 
fluorescence microscopy and this is supported by the flow cytometry results. These 
results show a clear shift to the cells being less intensely GFP positive for shLMO1 
#6 when compared to shFF3, an shRNA directed towards the firefly luciferase gene, 
which is not present in normal cells so acts as a negative control (Fig 7.6a). This was 
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replicated in LMO1 GFP over-expressing PUER cells which were infected with the 
shLMO1 constructs. These results show a clear shift to being less GFP positive in 
both constructs #4 and #6 when compared to the normal overexpressing PUER cells 
(Fig 7.6b).
Figure 7.6. a) Flow Cytometry analysis of plat-e cells co-transfected with an LMO1 
GFP expression construct and shLMO1 constructs (Red - shGFP, Green - shFF3, 
Blue - shLMO1 constructs). b) Flow Cytometry analysis of LMO1 GFP expressing 
PUER cells infected with shLMO1 constructs (Red - LMO1 GFP, Green - Uninfected 
cells, Blue - shLMO1 constructs.) 
FlagLMO1 and FlagLMO4
Over-expressing PUER clones for LMO1 and LMO4 were also remade with the 
addition of the flag sequence so that the reliability of specific antibodies for LMO1 
and LMO4 could be assessed. The overexpression flag constructs were first tested in 
Plat-E cells and analysed by western blotting using α-Flag, α-LMO1 and α-LMO4. 
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This showed that the flag constructs worked successfully against the Plat-E negative 
control (Fig 7.7).
Figure 7.7. Western blot showing protein extract from Plat-E cells (PE) and Plat-E 
cells transfected with over expression constructs for Flag-LMO1 (FLMO1) and Flag-
LMO4 (FLMO4).. Using both LMO and Flag primary antibodies to demonstrate the 
presence of both constructs and li-cor 800 secondary antibodies.
After transfection of PUER cells with the Flag constructs western blots were carried 
out using PUER nuclear extract to test the constructs. In western blots the flag 
constructs were shown to work with the LMO2 antibody and the use of anti-flag 
antibody demonstrated the functioning of the constructs in PUER cells. The use of 
the LMO2 antibody and construct acted as a control as the expression of LMO2 is 
well documented. The LMO4 antibody was also shown to work with flag-LMO4 in 
both PUER nuclear extract and Plat-E cells, however the level of LMO4 in normal 
PUER nuclear extract was not high enough to  be detected (Fig 7.8).
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Figure 7.8. Western blots showing LMO2, LMO4 and Flag antibodies on Flag-LMO2, 
Flag-LMO4 and PUER cell nuclear extract.
shLMO4 PUER cells
PUER cells were infected with the shLMO4 construct to knock-down LMO4 
production and an infection of PUER cells with MigRI was also carried out as a 
negative control, giving only GFP expression. The initial construct used a hygromycin 
resistance gene to allow for selection of successfully infected cells. In all replicates of 
this experiment all cells died within one week of infection and outgrowth of resistant 
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clones was unsuccessful. To ascertain whether this was a result of poor infection 
efficiency or a phenotype of the knock-down a new shLMO4 construct was produced, 
containing the GFP gene instead of the hygromycin resistance gene. One day after 
the infection the cells were analysed visually by fluorescence microscopy. This 
analysis showed at this time point a relatively low (~15%) proportion of GFP+ cells, 
indicating that a number of cells were becoming GFP positive. Further infections 
were carried out to allow for investigation into a possible phenotype. Following 
infection, a proportion of the cells were sorted at day 2 after infection by FACS into 
GFP positive and negative fractions. In this initial sort 30.59% of the MigRI cells were 
GFP-positive and 29.16% of the shLMO4 sorted cells were GFP–positive, showing a 
relatively high infection efficiency and an equivalent percentage to the control (Fig 
7.9). At day 3 a sample of the unsorted cells was analysed by flow cytometry and this 
showed the GFP-positive fraction for the MigRI transfected cells to be still at 27.97%, 
however, for the shLMO4 transfected cells this had dropped to only 15.06%  (Table 
7.1). Further measurements were taken on days 4, 5, 6 and 8 and on each occasion 
the percentages remained at a similar level (Table 7.1, Fig 7.9).
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Figure 7.9. FACS plots for sorting of MigRI infected PUER cells and shLMO4 
infected PUER cells on days 1 and 5 post infection. The sorting uses a combination 
of FITC and PE detection to detect and sort the GFP positive cells. R3 shows the 
percentage of GFP positive cells present within the population. The gating on Day 5 
was stricter than Day 1 to ensure that only the most GFP positive cells were 
selected.
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Table 7.1. Percentage of GFP positive cells within an unsorted population of infected 








To confirm that the knockdown of LMO4 had been successful RNA extractions were 
carried out on sorted cells and cDNA produced for qPCR. The qPCR results showed 
a knockdown efficiency of 51% comparing PUER cells to shLMO4 PUER cells and 
55% comparing the MigRI control to shLMO4 PUER cells (Fig 7.10) Following the 
discovery that shLMO4 PUER cells had a significant survival problem apoptosis 
assays were carried out. A comparison was carried out between MigRI PUERs and 
shLMO4 PUERs looking at Annexin V and PI staining. The results showed a higher 
percentage 14% of shLMO4 cells in an apoptotic/necrosis state when compared to 
3% of MigRI cells (Fig 7.11).
Figure 7.10. RNA Expression of shLMO4 PUER cells versus uninfected cells and 
MigRI infected cells.
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Figure 7.11. Apoptosis assay at day 2 following infection using Annexin V (APC 
staining) and PI (PE channel). R4= Healthy cells, R2= cells committed to apoptosis, 
R3= apoptotic cells with a permeable membrane and R5 = dead cells/necrotic cells.
shLMO1 and shLMO4 A2lox cells
A2lox cells are inducible ES cells which means that the Flag-LMO1 and shLMO1 
constructs can be activated at different time points through differentiation by the 
addition of doxycyclin. Initial trials showed that in uniduced Flk+ cells containing the 
Flag-LMO1 construct a high level of LMO1 was expressed when compared to the 
Flk- undifferentiated cells. When induced the cells showed a 276% increase in LMO1 
expression demonstrating that the induction system worked effectively (Fig 7.12). 
The shLMO1 construct was analysed by FACS looking at the cKit (APC), CD41 (PE-
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Cy7) and Tie2 (PE) markers. Gating on the c-kit+ cells, there appeared to be a 
decrease in the percentage becoming CD41+ in the induced LMO1 overexpressing 
(8%) and more so in the knockdown (5%) when compared to the uninduced cells, 
which were remarkably constant between the two cell lines (both 11%) (Fig 7.13).
Figure 7.12. qPCR expression profile for LMO1 in Flk+ cells containing the Flag-
LMO1 construct before and after induction with doxycyclin. 
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Figure 7.13. Flow cytometry results showing the percentage of A2Lox cells 
differentiating to Tie2+ CD41+ during induction of Flag-LMO1 and shLMO1 (R4). On 
induction of LMO1 over-expression (Flag-LMO1) the percentage of cells drops from 
10.72% to 7.63% and on induction of the LMO1 knockdown (shLMO1) the 
percentage reduces from 10.51% to 4.84%.
We then investigated the efficiency of the shLMO4 construct in the A2lox clones. The 
level of LMO4 expression in shLMO4 A2lox ES cells was shown to be significantly 
lower than in  control A2lox ES cells and unexpectedly remained unchanged after 
induction (Fig 7.14). 
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Figure 7.14. qPCR expression profile for LMO4 in ES cells and in shLMO4 A2lox 
cells before and after induction with doxycyclin. shLMO1 Flk+ A2lox cells were also 
included as a control to check that shLMO1 did not influence LMO4 expression.
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DISCUSSION
The LMO family of proteins have all been linked with both embryonic development 
and a range of cancers which makes them very relevant to study in relation to 
hematopoiesis. It has been shown that LMO2 is crucial in the early stages of 
hematopoeisis and as a result of the high similarity between members of the LMO 
family it is logical to assume that LMO1 and LMO4 may also be involved in this 
process. LMO1 has been directly linked to hematopoiesis through its involvement in 
T-ALL and has been shown to be expressed only at the haemangioblast stage, 
however its exact role in non-T-ALL cells is not well understood. LMO4 has not been 
directly linked to hematopoiesis, but has been linked to neural development and is 
expressed in many tissues including those at the developmental stages of 
hematopoiesis. 
LMO1 and LMO4 Expression
The expression was analysed by qPCR using the cDNA from the various cells used 
in this study. LMO1 showed the highest level of expression of the LMOs within the 
Flk+ cells with background levels in undifferentiated ES cells and PUER cells. 
Previous studies have also shown the expression levels of LMO1 to be very low 
within the hematopoietic development lineage except in the case of T-ALL where it 
can be upregulated and act in a similar way to LMO2 (Oram, et al. 2013). It is 
interesting that a temporary upregulation may occur at the Flk+ stage which suggests 
a role for LMO1 at this stage. This may mean that LMO1 is linked to differentiation of 
haemangioblasts into different lineages. As LMO1 and LMO2 act in a similar way it is 
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also possible that overexpression of LMO1 may prevent the developmental block 
seen with LMO2 knockdown.  LMO4 overall showed less dynamic changes in its 
expression levels than the other LMO proteins, however, the results do demonstrate 
a rise in expression level between the undifferentiated ES cells and the Flk+ cells. A 
continued level of expression is then also seen into the myeloid lineage through 
PUER cells and differentiated PUER cells.  Kenny, et al. (1998) showed a similar 
maintained level of expression through the lymphoid lineage supporting a role for 
LMO4 within hematopoiesis. LMO4 is also know to be much more widely expressed 
than the other LMO proteins so may have a more general developmental role across 
many cell types (Sum, et al. 2005a). 
Finally, the involvement of LMO2 in hematopoiesis is very well documented.The 
mRNA expression results show a peak in expression at the Flk+ stage and a 
significant drop in expression by the differentiated PUER stage. Liu, et al. (2012) 
indeed showed that LMO2 was significantly upregulated in Flk+ cells heading 
towards a hematopoietic fate. It has also been shown that the level is downregulated 
again throughout myeloid differentiation (Natkunam, et al. 2007). In the lymphoid 
lineage LMO2 is also downregulated. In particular in T-cells LMO2 is completely 
silenced during the double negative stages and overexpression can lead to increased 
cell proliferation followed by T-ALL (Matthews, et al. 2013). Neither the myeloid nor 
lymphoid lineage shows any LMO2 expression by the fully differentiated cell stage 
and this can also be seen in the results of this study with the significant down 
regulation between the myeloid progenitor (PUER cells) and their 2 day differentiated 
state (Kenny, et al. 1998).
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LMO1 and LMO4 Knockdown Constructs
To achieve knockdown of LMO1 and LMO4 small hairpin (sh) constructs were 
produced based on the siRNA principle. Small interfering RNAs (siRNAs) are a 
naturally occurring method of downregulating expression of a gene. They act by 
forming a double stranded RNA fragment which is cut into smaller fragments by the 
enzyme Dicer. It is thought this probably originally developed as a defence against 
RNA viruses. The RNA fragments then bind to complementary mRNA strands 
resulting in the digestion of these strands and mRNA being degraded and therefore 
not translated (NIGMS, 2013). siRNAs can also function without full complementarity	   
by inhibition of RNA translation. Using shRNA is more effective than using siRNA 
because the shRNA is introduced into the cell in DNA form and integrated into the 
hosts genome before being expressed at high levels and forming RNA hairpins which 
can be cleaved by the Dicer enzyme. This is advantageous because a much smaller 
quantity of DNA is required than siRNA and also DNA is much more stable and 
constitutively present within the cells (Rao, et al. 2009). 
The shRNAoligos for LMO1 and LMO4 were produced and the vector used to 
introduce these into the cells was the pPrime (MSCV) vector which is based on the 
MigRI vector.  The PCR stage of the protocol had to be optimised due to poorly 
separating fragments causing the supposedly removed fragment to be ligated back in 
at a higher frequency than the insert. The constructs were then transfected into Plat-
E retro-viral packaging cells in preparation for infection of PUER cells. To test the 
success of the constructs before moving into another cell type a co-transfection with 
a previously developed overexpression vector for each protein was carried out. For 
the shLMO1 constructs transfection of PUER cells expressing LMO1 were also 
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carried out. When these were analysed by FACS a clear shift from the highest GFP 
intensity was seen in construct #6 indicating that this construct was most effective at 
knocking own the LMO1 protein.
The main cells used in this study were PUER cells which are myeloid progenitors 
with inducible PU.1 expression. These cells were developed by Laslo et al. (2007) 
who showed that in the myeloid lineage PU.1 upregulation is required for progression 
from a multipotent precursor cell to myeloid cells. By making a construct where the 
PU.1 proteins merged to the estrogen receptor (ER) ligand binding domain, 
functional PU.1 protein is induced by addition of the synthetic estrogen OHT.This 
created a cell line which remains as a multipotent myeloid precursor until 
differentiation is required. These cells are not very early in the hematopietic lineage 
so are only able to differentiate into myeloid cells but they are still a useful starting 
point for testing new constructs as they are easy to culture and maintain and can be 
induced to differentiate. 
shLMO1
The initial three shLMO1 constructs which were successfully produced were 
unsuccessful in their ability to knockdown LMO1. However two constructs out of the 
second batch of four showed a clear knockdown when infection of LMO1 expressing 
PUER cells was carried out. One of these, shLMO1 #6, was then used to reclone into 
p2lox and was electroporated into the A2lox ES cells. 
The A2lox system is an inducible system allowing a construct to be induced at 
desired time points throughout the cell differentiation process by addition of 
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doxycyclin. Initial trials were carried out with Flag-LMO1 which showed an almost 3 
fold increase when induced in Flk+ cells. This confirmed that the system functions 
correctly and these cells can be later used to study the effects of increased levels of 
LMO1. 
A potentially interesting result was shown for shLMO1 when induced it showed a 
clearly lower percentage of cells becoming CD41 positive. The CD41 marker is 
generally associated with hematopoietic progenitor cells so this result suggests a 
possible involvement of LMO1 in the differentiation from haemangioblasts to early 
stage hematopoietic progenitors. This could suggest that the expression of LMO1 is 
necessary for the transition from haemangioblast to hemogenic endothelium. 
However, as this can only be assessed in the small fraction of the population which is 
also c-Kit positive the result is based on  a very small change in the number of 
shLMO1 cells. It therefore needs to be repeated several times before conclusions 
can be made. There is also a question about these results due to the unsuccessful 
induction of shLMO4 constructs. This could suggest an overall problem with using 
this inducible system for sh knockdown. Despite the Hoogenkamp group successfully  
using it for the knockdown of LMO2 at the haemangioblast stage, further controls will 
need to be performed to be certain about the knockdown efficiency in these cell lines.
As demonstrated in the qPCR expression results PUER cells do not express 
appreciable levels of LMO1, so it was not expected to see a phenotype in these cells. 
Previous studies have shown a clear involvement of LMO1 overexpression in T-ALL 
which appears to be mostly attributed to its close similarity to LMO2, the two proteins 
almost being interchangeable in the pathways involved in T-ALL development. There 
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is evidence to suggest that LMO1 may be involved in hematopoiesis due to its 
binding partners. During thymic T-cell development  LMO1 has been shown to form a 
complex with SCL which can inhibit the transcriptional activation action of E2A. It has 
been shown that the presence of the LMO1-SCL complex is necessary in the early 
stages of T-cell differentiation but is downregulated throughout the differentiation 
process, in cases where it is not downregulated T-ALL develops (Herblot, et al. 
2000). This demonstrates a clear involvement of LMO1 in hematopoiesis, however 
there is still no real evidence of an exclusive role which is not also fulfilled by LMO2. 
The initial results in this study have shown a potential for LMO1 having an exclusive 
role in early hematopoiesis. To further these findings follow up studies are required to 
assess the effect of shLMO1 when it is induced at various stages throughout the 
differentiation process. It may also be important to look at the presence of any 
compensatory mechanism between LMO1 and the other members of the LMO family 
as this has already been shown between LMO1 and LMO3 in neural development 
(Tse, et al. 2004).
shLMO4
Functional sh constructs for LMO4 were produced and this was demonstrated in co-
transfected Plat-E cells. When PUER cells were infected with the initial hygromycin 
resistance construct selection with hygromycin failed on each occasion due to the 
death of all cells. This meant that it was impossible to differentiate between the 
infection efficiency and any cell death phenotype of the construct. To solve this 
problem a construct with GFP rather than hygromycin resistance was produced. This 
meant that selection could then be carried out by FACS and a visual indicator could 
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also be seen to show that the infection was successful. The cells resulting from this 
were sorted showing around a 30% infection efficiency for both MigRI and shLMO4 
from the Plat-E cell supernatant. The ~30% efficiency of infection achieved was much 
lower than that which would be expected in adherent cells however was very good 
for non-adherent cells and as this was carried out on a quantity of 4.5x106 cells this 
gave an acceptable number to study (Cell Biolabs, 2012).
The cell death phenotype which was seen in the hygromycin selection was partially 
confirmed in the GFP cells. When analysed there was a clear fall of ~50% in the 
percentage of GFP cells by the second day in the shLMO4 cells as opposed to the 
MigRI cells. The percentage after this first drop however remained relatively constant 
for both genotypes. This suggested that the lack of LMO4 may be activating an 
apoptotic pathway or disrupting the cell cycle in some way.  In an attempt to further 
elucidate the reason for this, apoptosis assays were carried out using PI and Annexin 
V. The Annexin V apoptosis assay works by antibody binding to the 
phosphatidylserine which is normally present on the inner surface of the cell 
membrane and becomes exposed on the outer cell surface during apoptosis. At later 
stages of apoptosis and during necrosis the cell membrane breaks down, allowing PI 
into the cellsʼ nucleus, staining the DNA (Vermes, et al. 1995). It was shown that at 
day 2 after infection there were clearly higher levels of apoptotic activity in shLMO4 
cells when compared to MigRI control cells. This result would suggest a crucial role 
for LMO4 within myeloid progenitor cells at this stage.
LMO4 is highly expressed in most proliferating epithelial tissue and in cells derived 
from epithelial tissue and has been shown in many studies to be linked to breast 
cancer with overexpression being linked to poor prognosis (Sum, et al. 2005a & Sum, 
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et al. 2005b). It has also been shown that LMO4 is critical for definitive erythropoiesis 
and is highly expressed in other definitive hematopoietic progenitors, particularly 
early T-cell progenitors. In a similar way to LMO1 and LMO2, no expression is seen 
in fully differentiated T-cells. In hematopoiesis LMO4 has been shown to form a 
complex with ldb1, eto-2 and cdk9, which is necessary for the transcriptional 
activation of Runx1, which is a required transcription factor for definitive 
hematopoiesis (Romano & Giordano, 2008, Lancrin, et al. 2009 & Sturgeon, 2013).
From these studies it is clear that LMO4 has a role in hematopoiesis as well as 
epithelial cell proliferation and cancers. This does not however fully explain the 
reason for the apparent apoptotic affect seen in PUER cells. A potential route for this 
is through the interaction identified by Meier, et al. (2006) with cdk9 which is involved 
in many processes including cell growth, proliferation and anti-apoptotic protection 
(Romano & Giordano, 2008). Wang, et al. (2012) showed that CDK9 inhibition is a 
key regulator in the apoptosis of neutrophils, a later cell in the myeloid lineage. It was 
shown that when CDK9 was inhibited the level of Mcl-1, an anti-apoptotic protein, 
reduced causing rapid apoptosis. It is possible therefore that a drop in the level of 
LMO4 could reduce expression of CDK9 and lead to apoptosis within PUER cells. 
Cell cycle disruption and apoptosis by LMO4 has also been shown in breast cancer 
cells at the G2/M stage (Montañez‐Wiscovich, et al. 2010). A reduction in the level of 
LMO4 resulted in amplification of centromeres, abnormal spindles and increased cell 
death. Again this could be a route for the apoptotic effect seen in PUER cells and 
further study is required to establish whether this is a possibility.
There are however complications to this finding. Firstly, the increased apoptotic level 
demonstrated here is measured at the second day by which time the main fall in cell 
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population has already occurred. It is therefore likely that this is the remaining 
fraction of apoptotic cells following the initial phase of cell death. Measurements at 
day1, when not all infected cells fully express the transgene yet, should give more 
insight. A further complication is that in a later flow cytometry analysis of sorted 
shLMO4 cells it was shown that after more than one week, there was a significant 
population of GFP negative. A possible cause for this would be the loss of transgene 
expression however this seems unlikely as the shRNA and GFP have independent 
promoters.  Another possibility is that this population is apoptotic cells which have 
lost their GFP before falling apart and this is supported by the high proportion of cells 
in this population which were dead or dying, this argues against the possibility that 
these are healthy cells outgrowing the GFP positive cells.
Unfortunately, when introduced into the A2lox ES cell system the expression levels 
for the shLMO4 cells did not show a reduction in LMO4 expression when induced. 
They did however show a significantly lower level of LMO4 than untargeted cells. 
This suggests that the construct in this ES cell clone is constitutively active.. 
Alternative clones, with the same shRNA, have been frozen at an early stage and will 
be checked for their functionality. Further studies will therefore be required to 
establish whether the A2lox system is fully appropriate for sh knockdown. 
Overall this study forms the basis for a large amount of future work into the roles of 
LMO1 and LMO4 within hematopoesis. A set of useful and functional tools have been 
developed which can now be used to study and attempt to understand the roles 
which these proteins play. Initial results within PUER cells show a definite 
involvement of LMO4 in cell function, at least partially through apoptosis. Future work 
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to identify the partners of LMO4 would help to understand whether there is a link to 
CDK9 and apoptosis by this route. The ES cell constructs are also exciting tools for 
future study, however, confirmation that the inducible system functions correctly with 
sh constructs will be required.
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